Systems, apparatuses, and methods for delivery of pulsed electric field ablative energy to endocardial tissue

Description

BACKGROUND

The generation of pulsed electric fields for tissue therapeutics has moved from the laboratory to clinical applications over the past two decades, while the effects of brief pulses of high voltages and large electric fields on tissue have been investigated for the past forty years or more. Application of brief high DC voltages to tissue may generate locally high electric fields typically in the range of hundreds of volts per centimeter that disrupt cell membranes by generating pores in the cell membrane. While the precise mechanism of this electrically-driven pore generation or electroporation continues to be studied, it is thought that the application of relatively brief and large electric fields generates instabilities in the lipid bilayers in cell membranes, causing the occurrence of a distribution of local gaps or pores in the cell membrane. This electroporation may be irreversible if the applied electric field at the membrane is larger than a threshold value such that the pores do not close and remain open, thereby permitting exchange of biomolecular material across the membrane leading to necrosis and/or apoptosis (cell death). Subsequently, the surrounding tissue may heal naturally.

While pulsed DC voltages may drive electroporation under the right circumstances, there remains an unmet need for thin, flexible, atraumatic devices that effectively deliver high DC voltage electroporation ablation therapy selectively to endocardial tissue in regions of interest while minimizing damage to healthy tissue.

BRIEF SUMMARY

Described here are systems, devices, and methods for ablating tissue through irreversible electroporation. In some embodiments, an apparatus can include a first shaft having a longitudinal axis and defining a lumen; a second shaft disposed within the lumen and having a distal portion that extends from a distal portion of the first shaft, the second shaft moveable along the longitudinal axis relative to the first shaft; a first electrode coupled to the distal portion of the first shaft; a second electrode coupled to the distal portion of the second shaft, the first and second electrodes configured to generate an electric field for ablating tissue; and an inflatable member disposed between the first and second electrodes, the inflatable member configured to transition from an undeployed configuration to a deployed configuration in response to the second shaft being moved proximally relative to the first shaft, the inflatable member in the deployed configuration configured to engage a wall of a pulmonary vein ostium and direct the electric field generated by the first and second electrodes toward the wall.

In some embodiments, an apparatus can include a shaft having a longitudinal axis and defining a lumen; an inflatable member disposed near a distal portion of the shaft, the inflatable member configured to transition between an undeployed configuration and a deployed configuration, the inflatable member including a wall having a proximal portion, a distal portion, and a middle portion disposed between the proximal and distal portions of the wall, the middle portion having a minimum thickness that is less than a thickness of the proximal and distal portions of the wall; and first and second electrodes disposed on opposite sides of the inflatable member along the longitudinal axis, the first and second electrodes configured to generate an electric field for ablating tissue.

In some embodiments, a system can include a signal generator configured to generate a pulse waveform; an ablation device coupled to the signal generator, the ablation device including: first and second electrodes configured to receive the pulse waveform and generate an electric field for ablation; and an inflatable member formed of an insulating material and disposed between the first and second electrodes, the inflatable member configured to transition between an undeployed configuration in which the inflatable member can be advanced to a pulmonary vein ostium to a deployed configuration in which the inflatable member can engage with a wall of the pulmonary vein ostium, the inflatable member in the deployed configuration configured to direct the electric field toward the wall.

In some embodiments, a method can include retracting an inner shaft of an ablation device relative to an outer shaft of the ablation device, the inner shaft disposed within a lumen of the outer shaft; transitioning, in response to retracting the inner shaft relative to the outer shaft, an inflatable member of the ablation device from an undeployed configuration to a deployed configuration in which a side portion of the inflatable member engages a wall of a pulmonary vein ostium; and delivering, after the transitioning, a pulse waveform to first and second electrodes of the ablation device such that the first and second electrodes generate an electric field for ablating the wall of the pulmonary vein ostium, the first and second electrodes disposed on opposite sides of the inflatable member.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a block diagram of an electroporation system, according to embodiments.

FIG. 2A is a side view of an ablation device in an inflated state, according to embodiments.

FIG. 2B is a side view of an ablation device depicted in FIG. 2A in a deflated state, according to embodiments.

FIG. 3 is a cross-sectional side view of an ablation device disposed in a pulmonary vein, according to embodiments.

FIG. 4A is a cross-sectional side view of an ablation device disposed in a pulmonary vein, according to embodiments. FIG. 4B is a perspective view of an ablation zone associated with the ablation device depicted in FIG. 4A when disposed in a pulmonary vein, according to embodiments.

FIG. 5A is a cross-sectional side view of an ablation device disposed in a pulmonary vein, according to embodiments. FIG. 5B is a cross-sectional side view of the ablation device depicted in FIG. 5A disposed in a pulmonary vein.

FIG. 6A is a cross-sectional side view of an ablation device disposed in a pulmonary vein, according to embodiments. FIG. 6B is a cross-sectional side view of an ablation zone of the ablation device depicted in FIG. 6A disposed in a pulmonary vein.

FIG. 7 is a side view of an ablation device, according to embodiments.

FIG. 8 is a side view of an ablation device, according to embodiments.

FIG. 9 is a perspective view of an ablation device, according to embodiments.

FIG. 10 is a schematic side view of a portion of a wall of an inflatable member of an ablation device, according to embodiments.

FIG. 11 is a schematic side view of a portion of a wall of an inflatable member of an ablation device, according to embodiments.

FIGS. 12A and 12B are different views of an ablation device, according to embodiments.

FIG. 13 is a cross-sectional side view of the ablation device depicted in FIGS. 12A and 12B.

FIG. 14 is a cross-sectional side view of an ablation zone of the ablation device depicted in FIGS. 12A and 12B.

FIG. 15 is an example waveform showing a sequence of voltage pulses with a pulse width defined for each pulse, according to embodiments.

FIG. 16 schematically illustrates a hierarchy of pulses showing pulse widths, intervals between pulses, and groupings of pulses, according to embodiments.

FIG. 17 provides a schematic illustration of a nested hierarchy of monophasic pulses displaying different levels of nested hierarchy, according to embodiments.

FIG. 18 is a schematic illustration of a nested hierarchy of biphasic pulses displaying different levels of nested hierarchy, according to embodiments.

FIG. 19 illustrates schematically a time sequence of electrocardiograms and cardiac pacing signals together with atrial and ventricular refractory time periods and indicating a time window for irreversible electroporation ablation, according to embodiments.

FIGS. 20A-20B illustrates a method for tissue ablation, according to embodiments.

DETAILED DESCRIPTION

Described here are systems, devices, and methods for ablating tissue through irreversible electroporation. Generally, an apparatus for delivering a pulse waveform to tissue may include a first catheter (e.g., shaft) defining a longitudinal axis. An expandable/inflatable member may be coupled to a distal portion of the first catheter. A first electrode may be coupled to the distal portion of the first catheter and proximal to the inflatable member. A second catheter (e.g., shaft) or tubular lumen may be disposed within a lumen of the first catheter and a chamber of the expandable/inflatable member where the second catheter may be slidable relative to the first catheter. The expandable/inflatable member may be coupled to a distal end of the second catheter. A second electrode may be coupled to the distal portion of the second catheter and distal to the inflatable member. In some embodiments the second catheter, and in particular its distal portion, may be steerable linearly relative to the first catheter. Thus in some embodiments, the second electrode may be steerable relative to the first electrode. A proximal portion of the expandable/inflatable member may be coupled to the distal portion of the first catheter and a distal portion of the expandable/inflatable member may be coupled to the distal portion of the second catheter or tubular lumen. The second catheter may have a lumen diameter sufficient to pass a guidewire through the lumen. The guidewire may provide mechanical support for the first and second catheters. In some embodiments, the first electrode may comprise a first set of electrodes and the second electrode may comprise a second set of electrodes.

Generally, a system for delivering a pulse waveform to tissue may include a signal generator configured for generating a pulse waveform and an ablation device coupled to the signal generator and configured to receive the pulse waveform. The ablation device may include an expandable/inflatable member (e.g., a balloon) coupled to a distal portion of a first catheter for delivering energy to ablate tissue by irreversible electroporation. One or more electrodes may be formed proximal to the expandable/inflatable member on a surface of the first catheter.

In some embodiments, a system may include a signal generator configured for generating a pulse waveform. An ablation device may be coupled to the signal generator and configured for receiving the pulse waveform. The ablation device may include a handle configured to move the second electrode relative to the first electrode. The system may include a cardiac stimulator for generation of pacing signals and for delivery of pulse waveforms in synchrony with the pacing signal. In some embodiments, one or more of the electrodes may have an insulated electrical lead associated therewith, the insulated electrical lead configured for sustaining a voltage potential of at least about 700 V without dielectric breakdown of its corresponding insulation, the insulated electrical lead disposed in a lumen of the catheter. In some embodiments, one or more of the electrodes may be independently addressable.

In some embodiments, a pulse waveform may include a first level of a hierarchy of the pulse waveform in the form of a first set of pulses, each pulse having a pulse time duration, a first time interval separating successive pulses. A second level of the hierarchy of the pulse waveform includes a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first sets of pulses, the second time interval being at least three times the duration of the first time interval. A third level of the hierarchy of the pulse waveform includes a plurality of second sets of pulses as a third set of pulses, a third time interval separating successive second sets of pulses, the third time interval being at least thirty times the duration of the second level time interval. In some of these embodiments, the pulse waveform includes a fourth level of the hierarchy of the pulse waveform includes a plurality of third sets of pulses as a fourth set of pulses, a fourth time interval separating successive third sets of pulses, the fourth time interval being at least ten times the duration of the third level time interval.

In some embodiments, a distal portion of the ablation device may further include a radiopaque portion. In some embodiments, the second catheter defines a lumen therethrough.

In some embodiments, a method of ablation via irreversible electroporation includes the steps of advancing an ablation device towards a pulmonary vein ostium. The ablation device may include a first catheter, a second catheter or tubular lumen, and an expandable/inflatable member coupled to a distal end of the catheter shaft. The inflatable member may be flanked by electrodes mounted on the device proximal and distal to the inflatable member. A pulse waveform may be generated. The pulse waveform may be delivered to the pulmonary vein ostium via the electrodes on the ablation device.

In some embodiments, the expandable/inflatable member of the ablation device may be transitioned from a first configuration to a second configuration. In some embodiments, transitioning the expandable/inflatable member from the first configuration to the second configuration includes infusing the expandable/inflatable member with distilled or deionized water which may induce mechanically expansion. In some embodiments, pulsed electric field ablation energy may be delivered through the first set of electrodes and the second set of electrodes of the ablation device. In some embodiments, the ablation device is configured to generate an electric field intensity of between about 200 V/cm and about 800 V/cm.

In some embodiments, the ablation device may include a handle. In some embodiments, a portion of the first catheter shaft proximal to the proximal or first set of electrodes can be deflectable, with the deflection controlled by a knob or other control mechanism on the handle. The method may further include the steps of deflecting a portion of the ablation device using the handle. For example, a second electrode may be moved relative to the first electrode and the shape of the expandable/inflatable member in the second configuration may be modified by infusion of distilled or deionized water through an infusion port attached to the handle, and the distal shaft may be deflected using a deflection knob on the handle.

In some embodiments, the method may include the steps of creating a transseptal opening into a left atrium, advancing a guidewire and a steerable sheath into the left atrium through the transseptal opening, and advancing the ablation device into a pulmonary vein over the guidewire. In some embodiments, the method may include the steps of creating a first access site in a patient, advancing the guidewire through the first access site and into a right atrium, advancing the dilator and a steerable sheath over the guidewire and into the right atrium, advancing the dilator from the right atrium into the left atrium through an interatrial septum to create the transseptal opening, and dilating the transseptal opening using the dilator. In some embodiments, a second access site may be created in the patient for advancing a cardiac pacing catheter. In some embodiments, the method may include the steps of advancing the pacing catheter into a right ventricle, generating a pacing signal for cardiac stimulation of the heart using the cardiac stimulator, and applying the pacing signal to the heart using the cardiac stimulator, and then delivering a pulsed electric field voltage pulse waveform in synchronization with the pacing signal once the ablation device with the inflatable member is suitably positioned at a pulmonary vein ostium.

In some embodiments, the method may include the step of fluoroscopically imaging a radiopaque portion of the ablation device during one or more steps. In some embodiments, the first access site is a femoral vein. In some embodiments, the interatrial septum includes a fossa ovalis.

In some embodiments, the pulse waveform may include a first level of a hierarchy of the pulse waveform in the form of a first set of pulses, each pulse having a pulse time duration, a first time interval separating successive pulses. A second level of the hierarchy of the pulse waveform includes a plurality of first sets of pulses as a second set of pulses, a second time interval separating successive first sets of pulses, the second time interval being at least three times the duration of the first time interval. A third level of the hierarchy of the pulse waveform includes a plurality of second sets of pulses as a third set of pulses, a third time interval separating successive second sets of pulses, the third time interval being at least thirty times the duration of the second level time interval. In some of these embodiments, the pulse waveform includes a fourth level of the hierarchy of the pulse waveform includes a plurality of third sets of pulses as a fourth set of pulses, a fourth time interval separating successive third sets of pulses, the fourth time interval being at least ten times the duration of the third level time interval.

The systems, devices, and methods described herein may be used to generate large electric field magnitudes at desired regions of interest to generate irreversible electroporation. An irreversible electroporation system as described herein may include a signal generator and a processor configured to apply one or more voltage pulse waveforms to a set of electrodes to deliver energy to a region of interest. The pulse waveforms disclosed herein may aid in therapeutic treatment of cardiac arrhythmias such as atrial fibrillation. In order to deliver the pulse waveforms generated by the signal generator, one or more electrodes of the ablation device may have an insulated electrical lead configured for sustaining a voltage potential of at least about 700 V without dielectric breakdown of its corresponding insulation. In some embodiments, at least some of the electrodes may be independently addressable such that each electrode may be controlled (e.g., deliver energy) independently of any other electrode of the device.

The term “electroporation” as used herein refers to the application of an electric field to a cell membrane to change the permeability of the cell membrane to the extracellular environment. The term “reversible electroporation” as used herein refers to the application of an electric field to a cell membrane to temporarily change the permeability of the cell membrane to the extracellular environment. For example, a cell undergoing reversible electroporation can observe the temporary and/or intermittent formation of one or more pores in its cell membrane that close up upon removal of the electric field. The term “irreversible electroporation” as used herein refers to the application of an electric field to a cell membrane to permanently change the permeability of the cell membrane to the extracellular environment. For example, a cell undergoing irreversible electroporation can observe the formation of one or more pores in its cell membrane that persist upon removal of the electric field.

Pulse waveforms for electroporation energy delivery as disclosed herein may enhance the safety, efficiency and effectiveness of energy delivery to tissue by reducing the electric field threshold associated with irreversible electroporation, thus yielding more effective ablative lesions with a reduction in total energy delivered. In some embodiments, the voltage pulse waveforms disclosed herein may be hierarchical and have a nested structure. For example, the pulse waveform may include hierarchical groupings of pulses having associated timescales. In some embodiments, the methods, systems, and devices disclosed herein may comprise one or more of the methods, systems, and devices described in one or more of International Application Serial No. PCT/US2016/057664, filed on Oct. 19, 2016, and titled “SYSTEMS, APPARATUSES AND METHODS FOR DELIVERY OF ABLATIVE ENERGY TO TISSUE,” and U.S. patent application Ser. No. 16/405,515, filed on May 7, 2019, and titled “SYSTEMS, APPARATUSES AND METHODS FOR DELIVERY OF ABLATIVE ENERGY TO TISSUE,” the contents of each of which are hereby incorporated by reference in its entirety.

In some embodiments, the systems may further include a cardiac stimulator used to synchronize the generation of the pulse waveform to a paced heartbeat. The cardiac stimulator may electrically pace the heart with a cardiac stimulator and ensure pacing capture to establish periodicity and predictability of the cardiac cycle. A time window within a refractory period of the periodic cardiac cycle may be selected for voltage pulse waveform delivery. Thus, voltage pulse waveforms may be delivered in the refractory period of the cardiac cycle so as to avoid disruption of the sinus rhythm of the heart. In some embodiments, an ablation device may include one or more catheters, guidewires, expandable/inflatable members, and electrodes. The ablation device may transform into different configurations (e.g., deflated and inflated) to position the device within an endocardial space.

Generally, to ablate tissue, one or more catheters may be advanced in a minimally invasive fashion through vasculature to a target location. The methods described here may include introducing a device into an endocardial space of the heart and disposing the device at the ostium of a pulmonary vein. A pulse waveform may be generated and delivered to electrodes of the device to ablate tissue. In some embodiments, the pulse waveform may be generated in synchronization with a pacing signal of the heart to avoid disruption of the sinus rhythm of the heart. In some embodiments, the electrodes may be configured in anode-cathode subsets. The pulse waveform may include hierarchical waveforms to aid in tissue ablation and reduce damage to healthy tissue.

I. Systems

Overview

Disclosed herein are systems and devices configured for tissue ablation via the selective and rapid application of voltage pulse waveforms to aid tissue ablation, resulting in irreversible electroporation. Generally, a system for ablating tissue described here may include a signal generator and an ablation device having one or more electrodes and an expandable/inflatable member (e.g., balloon) for the selective and rapid application of DC voltage to drive electroporation. As described herein, the systems and devices may be deployed endocardially to treat cardiac arrhythmias. Voltage pulse waveforms may be applied to a subset of the electrodes, with suitable anode/cathode electrode selections. A pacing signal for cardiac stimulation may be generated and used to generate the pulse waveform by the signal generator in synchronization with the pacing signal.

Generally, the systems and devices described herein include one or more catheters configured to ablate tissue in a ventricle of a heart. FIG. 1 illustrates an ablation system (100) configured to deliver voltage pulse waveforms. The system (100) may include an apparatus (120) including a signal generator (122), processor (124), memory (126), and cardiac stimulator (128). The apparatus (120) may be coupled to an ablation device (110), and optionally to a pacing device (130).

The signal generator (122) may be configured to generate pulse waveforms for irreversible electroporation of tissue, such as, for example, a pulmonary vein. For example, the signal generator (122) may be a voltage pulse waveform generator and be configured to deliver a pulse waveform to the ablation device (110). The return electrode (140) in some embodiments may be coupled to a patient (e.g., disposed on a patient's back) to allow current to pass from the ablation device (110) through the patient and then to the return electrode (140). In other embodiments, an electrode of the ablation device may serve as a return, such that a separate return electrode (140) may be absent. The processor (124) may incorporate data received from memory (126) to determine the parameters of the pulse waveform to be generated by the signal generator (122), while some parameters such as voltage can be input by a user. The memory (126) may further store instructions to cause the signal generator (122) to execute modules, processes and/or functions associated with the system (100), such as pulse waveform generation and/or cardiac pacing synchronization. For example, the memory (126) may be configured to store pulse waveform and/or heart pacing data for pulse waveform generation and/or cardiac pacing, respectively.

In some embodiments, the ablation device (110) may include a catheter having an expandable/inflatable member (e.g., balloon) configured to deliver the pulse waveforms described in more detail below. In each of the embodiments described herein, the expandable/inflatable member may be inflated using, for example, saline or, in some cases, an electrically non-conducting or very poorly conducting fluid (e.g., gas, liquid such as distilled water, deionized water, etc.). Fluid may be input through a lumen of a catheter coupled to the expandable/inflatable member. For example, the ablation device (110) may be introduced into an endocardial space and positioned at the ostium of a pulmonary vein and inflated so that the inflatable member is well apposed or engaged at the walls of the pulmonary vein, and then the pulse waveforms may be delivered to ablate tissue. The ablation device (110) may include one or more electrodes (112), which may, in some embodiments, be independently addressable electrodes. Each electrode may include an insulated electrical lead configured to sustain a voltage potential of at least about 700 V without dielectric breakdown of its corresponding insulation. In some embodiments, the insulation on each of the electrical leads may sustain an electrical potential difference of between about 200 V to about 3,000 V across its thickness without dielectric breakdown. For example, the electrodes (112) may be grouped into one or more anode-cathode subsets such as, for example, a subset including one proximal electrode and one distal electrode. In some embodiments, the distal electrode may include at least a portion of an expandable/inflatable member. As used herein, proximal is towards a handle of an ablation device and distal is towards a tip end of the ablation device.

When used, the pacing device (130) may be suitably coupled to the patient (not shown) and configured to receive a heart pacing signal generated by the cardiac stimulator (128). An indication of the pacing signal may be transmitted by the cardiac stimulator (128) to the signal generator (122). Based on detection of the pacing signal by the generator, a voltage pulse waveform may be generated by the signal generator (122) for ablation delivery. In some embodiments, the signal generator (122) may be configured to generate the pulse waveform in synchronization with the indication of the pacing signal (e.g., such that the ablation delivery occurs during a refractory window of a cardiac chamber). In some embodiments, the refractory window may be a common refractory window of two cardiac chambers such as an atrium and a ventricle. For example, in some embodiments, the common refractory window may start substantially immediately following a ventricular pacing signal (or after a very small delay) and last for a duration of approximately 250 ms or less thereafter. In such embodiments, an entire pulse waveform may be delivered within this duration.

The processor (124) may be any suitable processing device configured to run and/or execute a set of instructions or code. The processor may be, for example, a general purpose processor, a Field Programmable Gate Array (FPGA), an Application Specific Integrated Circuit (ASIC), a Digital Signal Processor (DSP), and/or the like. The processor may be configured to run and/or execute application processes and/or other modules, processes and/or functions associated with the system and/or a network associated therewith (not shown). The underlying device technologies may be provided in a variety of component types, e.g., metal-oxide semiconductor field-effect transistor (MOSFET) technologies like complementary metal-oxide semiconductor (CMOS), bipolar technologies like emitter-coupled logic (ECL), polymer technologies (e.g., silicon-conjugated polymer and metal-conjugated polymer-metal structures), mixed analog and digital, and/or the like.

The memory (126) may include a database (not shown) and may be, for example, a random access memory (RAM), a memory buffer, a hard drive, an erasable programmable read-only memory (EPROM), an electrically erasable read-only memory (EEPROM), a read-only memory (ROM), Flash memory, etc. The memory (126) may store instructions to cause the processor (124) to execute modules, processes and/or functions associated with the system (100), such as pulse waveform generation and/or cardiac pacing.

The system (100) may be in communication with other devices (not shown) via, for example, one or more networks, each of which may be any type of network. A wireless network may refer to any type of digital network that is not connected by cables of any kind. However, a wireless network may connect to a wireline network in order to interface with the Internet, other carrier voice and data networks, business networks, and personal networks. A wireline network is typically carried over copper twisted pair, coaxial cable or fiber optic cables. There are many different types of wireline networks including, wide area networks (WAN), metropolitan area networks (MAN), local area networks (LAN), campus area networks (CAN), global area networks (GAN), like the Internet, and virtual private networks (VPN). Hereinafter, network refers to any combination of combined wireless, wireline, public and private data networks that are typically interconnected through the Internet, to provide a unified networking and information access solution.

Ablation Device

The systems described here may include one or more multi-electrode ablation devices configured to ablate tissue in a pulmonary vein of a heart for treating indications such as arrhythmia. FIG. 2A is a side view of an ablation device (200) (e.g., structurally and/or functionally similar to the ablation device (110)) including a first catheter (203) (e.g., catheter shaft or outer shaft) defining a lumen, a second catheter (210) (e.g., a tubular guidewire or inner shaft defining a lumen), and an inflatable member (207). The second catheter (210) may be disposed within a lumen of the first catheter (203) and a chamber of the inflatable member (207) where the second catheter (210) may be slidable relative to the first catheter (203). The inflatable member (e.g., balloon) (207) may be coupled to the second catheter (210) such that the second catheter may pass through an inner chamber of the inflatable member (207). A first electrode (213) may be disposed on a surface of a distal portion (217) of the first catheter (203) and may be either separated from or attached to a proximal portion of the inflatable member (207). A second electrode (220) may be disposed on a distal portion (223) of the second catheter (210) and may be either separated from or attached to a distal portion of the inflatable member (207). The distal portion (223) of the second catheter (217) may be linearly moveable and about a portion distal to the first catheter (203). In some embodiments, the second electrode (223) may be moveable relative to the first electrode (213). A proximal portion of the inflatable member (207) may be coupled to the distal portion of the first catheter (203).

A proximal end of the inflatable member (207) may be attached proximal to a distal end of the first catheter (203). The first electrode (213) may be disposed on the first catheter (203) just proximal to the proximal end of the inflatable member (207). In FIGS. 2A-2B, the second catheter or tubular lumen (210) is shown as extending from the distal end (217) of the first catheter (203) and out of a distal end of the inflatable member (207). The second electrode (220) is disposed on a surface of the second catheter (210) proximal to the distal end (223) of the second catheter (210). The distal end of the inflatable member (207) may be attached to the second catheter (210) just proximal to the second electrode (220).

In some embodiments, a handle (not shown) may be coupled to a proximal portion of the ablation device (200) and may include a bending mechanism (not shown) (e.g., knob, switch, pull wires) configured to deflect a portion of the second catheter (210) just proximal to the first catheter (203). For example, operation of a pull wire of the handle may increase or decrease a curvature in a distal portion of the first catheter. A fluid port can attach to the handle for infusion of fluid such as distilled water or deionized water to inflate the inflatable member. In embodiments, the handle can incorporate a deployment mechanism configured to advance and retract the second catheter or guidewire lumen (210) such that a distance between the first electrode (213) and the second electrode (220) may be varied. For example, after the inflatable member is positioned suitably in a pulmonary vein, it can be inflated and well-apposed in the vein. Subsequently, the first electrode (213) and the second electrode (220) may be brought closer together by retracting the second catheter (210) relative to the first catheter (203). In this manner, the device may be configured for PEF ablation delivery.

The inflatable member (207) may be configured to transition between a first configuration (e.g., deflated inflatable member in FIG. 2B) and a second configuration (e.g., inflated inflatable member in FIG. 2A). The inflatable member (207) in the first configuration may be in a compact, deflated state suitable for advancement through vasculature. For example, the inflatable member (207) in the first configuration may be substantially empty of fluid, such as sterile distilled or deionized water or saline. In some embodiments, fluid may enter the inflatable member (207) via an infusion port of a handle coupled to the ablation device. The inflatable member (207) in the second configuration may hold a volume of saline or distilled or deionized water that fills and inflates the inflatable member (207) to an appropriate size and shape (e.g., having a diameter to contact a diameter of a pulmonary vein) under pressure from a syringe or other infusion device. The inflatable member (207) may transition to an intermediate configuration between the first and second configuration as necessary, for example, to conform to a lumen or advance the device through vasculature. In some embodiments, the inflatable member may be pressurized using one or more of a hand-operated syringe, pump, infusion device, combinations thereof, and the like. In some embodiments, an infusion pressure may be between about 2 psi and about 20 psi.

Although FIGS. 2A and 2B depict an ablation device having one proximal electrode (213) and one distal electrode (223), it should be appreciated that more electrodes can be used in other embodiments. For example, the first electrode (213) may include a set of electrodes (e.g., two or more proximal electrodes formed along a length of the first catheter). Likewise, the second electrode (220) may include a set of electrodes (e.g., two or more distal electrodes formed along a length of the second catheter). In some embodiments, a diameter of the electrodes (213, 220) may be between about 1 mm and about 6 mm, including all values and sub-ranges in between. A length of the electrodes (213, 220) (measured along a longitudinal axis of the first and second catheters) may be between about 1 mm and about 8 mm, including all values and sub-ranges in between. In some embodiments, a set of electrodes disposed on a surface of the first catheter (e.g., a set of two or more proximal electrodes (213)) may be spaced apart by between about 0.5 mm and about 9 mm, including all values and sub-ranges in between. In some embodiments, a set of electrodes disposed on a surface of the second catheter (e.g., a set of two or more distal electrodes (220)) may be spaced apart by between about 0.5 mm and about 9 mm, including all values and sub-ranges in between. In some embodiments, the inflatable member in a second configuration (e.g., inflated, deployed) may have an outer diameter (e.g., maximum width) of between about 20 mm and about 40 mm, including all values and sub-ranges in between. In some embodiments, the inflatable member in a first configuration (e.g., deflated, undeployed state) may have a length (measured along a longitudinal axis of the second catheter) of between about 10 mm and about 80 mm, including all values and sub-ranges in between, when the first and second electrodes (213, 220) are maximally separated.

FIG. 3 illustrates an ablation device (300) including an inflatable member (305) (e.g., structurally and/or functionally similar to the ablation device (110, 200)) in a second configuration (e.g., inflated) and deployed coaxially at an ostium of a pulmonary vein (301). The ablation device (300) includes a first electrode (311) coupled to a proximal end of the inflatable member (305) and a second electrode (313) coupled to a distal end of the inflatable member (305). A first catheter and a second catheter (e.g., a guidewire catheter defining a lumen), similar to those described herein, are not shown in FIG. 3 for the sake of clarity. In FIG. 3, the second catheter or guidewire lumen (not shown) has been retracted relative to the first catheter such that the first electrode (311) and second electrode (313) are minimally separated. When the inflatable member is in the second configuration and the first and second electrodes (311, 313) are retracted towards each other, a central region (308) of the inflatable member (305) may likewise be retracted towards each other or pulled in such that the proximal and distal ends of the inflatable member (305) are brought closer together. In this manner, the first and second electrodes (311, 313) may be at least partially surrounded by portions of the inflatable member (305) (where the balloon is folded inward).

FIG. 4A is a cross-sectional side view of an ablation device (400) (e.g., structurally and/or functionally similar to the ablation device (110, 200, 300)) disposed at a pulmonary vein ostium (402). In particular, a longitudinal axis of the ablation device (400) is disposed at an angle relative to a longitudinal axis of the pulmonary vein. FIG. 4B is a cross-sectional perspective view of an ablation zone (408) of the ablation device depicted in FIG. 4A disposed in a pulmonary vein (411). The ablation device (400) may include an inflatable member (404) and a first electrode (e.g., electrode proximal to the inflatable member (404)) and a second electrode (e.g., electrode distal to the inflatable member (404)). The first and second electrodes may be configured as an anode-cathode pair to deliver ablation energy to tissue. The ablation zone (408) may form a continuous ring-like shape on the pulmonary vein ostium (402) when the anode-cathode pair delivers energy that exceeds a threshold value required to generate irreversible electroporation.

FIG. 5A is a cross-sectional side view of an ablation device (500) (e.g., structurally and/or functionally similar to the ablation device (110, 200, 300, 400)) disposed in a pulmonary vein ostium (502) (e.g., deployed coaxially). The ablation device (500) includes a first electrode (508) coupled to a proximal end of the inflatable member (505) and a second electrode (509) coupled to a distal end of the inflatable member (505). Alternatively or in addition, the first and second electrodes may be respectively coupled to the distal portion of the first catheter proximal to the inflatable member and to the distal portion of the second catheter/guidewire lumen distal to the inflatable member. A first catheter or outer shaft and a second catheter or inner shaft (e.g., a guidewire lumen), similar to those described herein, are not shown in FIGS. 5A-5B for the sake of clarity. In FIG. 5A, the inflatable member (505) when inflated may form a frustum shape (e.g., a trapezoidal shape when viewed in lateral section). In some embodiments, a diameter of the inflatable member (505) at its widest portion may be between about 20 mm and about 40 mm, including all values and sub-ranges in between. A length of the inflatable member (505) (measured along a longitudinal axis of the first and second catheter) when fully deployed may be between about 3 mm and about 30 mm, including all values and sub-ranges in between. FIG. 5B is a cross-sectional side view of the ablation device (500) depicted in FIG. 5A where a longitudinal axis of the ablation device (500) is disposed at an angle relative to a longitudinal axis of the pulmonary vein (502).

FIG. 6A is a cross-sectional side view of an ablation device (600) (e.g., structurally and/or functionally similar to the ablation device (110, 200, 300, 400, 500)) disposed in a pulmonary vein ostium (603) (e.g., deployed coaxially). The ablation device (600) includes a first electrode (609) coupled to a proximal end of the inflatable member (606) and a second electrode (611) coupled to a distal end of the inflatable member (606). Additionally or alternatively, the first and second electrodes may be respectively coupled to the distal portion of the first catheter/outer shaft proximal to the inflatable member and to the distal portion of the second catheter/guidewire lumen distal to the inflatable member. A first catheter/outer shaft and a second catheter (e.g., an inner shaft defining a lumen), similar to those described herein, are not shown in FIGS. 6A-6B for the sake of clarity. The inflatable member (606) in the inflated configuration may form a rhombus-like shape in a lateral view, as shown in FIG. 6A. FIG. 6B is a lateral section view of an ablation zone (610) of the ablation device (600) depicted in FIG. 6A disposed in a pulmonary vein (603). The first and second electrodes (609, 611) may be configured as an anode-cathode pair to deliver ablation energy to tissue. The ablation zone (610) may form a ring-like shape on the pulmonary vein ostium (603) when the anode-cathode pair delivers energy that exceeds a threshold value required to generate irreversible electroporation.

FIG. 7 is a schematic cross-sectional side view of an ablation device (700) (e.g., structurally and/or functionally similar to the ablation device (110, 200, 300, 400, 500, 600)). The ablation device (700) may include a first catheter (703) (e.g., outer catheter shaft) defining a lumen, a second catheter (705) (e.g., an inner shaft defining a lumen), and an inflatable member (710). The second catheter (705) may be disposed within a lumen of the first catheter (703) and a chamber of the inflatable member (710) where the second catheter (705) may be slideable relative to the first catheter (703). The inflatable member (e.g., balloon) (710) may be coupled to the second catheter (705) such that the second catheter (705) may pass through an inner chamber of the inflatable member (710). A first electrode (707) may be disposed on a surface of a distal portion of the first catheter (703) and just proximal to the inflatable member (710). A second electrode (709) may be disposed on a distal portion (712) of the second catheter (705) and just distal to the inflatable member (710). The second catheter (705) may be linearly slideable relative to the first catheter (703). Thus, the second electrode (709) may be linearly slideable relative to the first electrode (707). A proximal portion of the inflatable member (710) may be coupled to the distal portion of the first catheter (703). In FIG. 7, the inflatable member (710) may form an approximately rhombus-like shape.

In some embodiments, the ablation device (700) may include a handle (not shown) coupled to a proximal portion of the ablation device (700) and may include a mechanism (not shown) (e.g., knob, switch, pull wires) configured to advance and retract the second catheter or guidewire (705) relative to the first catheter (703) such that a distance between the first electrode (707) and the second electrode (709) may be varied. For example, the first electrode (707) and the second electrode (709) may be brought closer together by retracting the second catheter (705) relative to the first catheter (703). In FIG. 7, a central portion (713) of a distal end of the inflatable member (710) is shown as retracted toward a proximal end of the inflatable member (710).

When suitably inflated, a proximal major portion (715) and a distal major portion (719) of the inflatable member (710) may be angled relative to a longitudinal axis of the first catheter (703) such that a surface of the inflatable member (710) forms an angle (731) with respect to the longitudinal axis that is greater than about 45 degrees. In some embodiments, a middle portion (721) of the inflatable member (710) may be relatively short compared to the major portions (715, 719).

Although FIG. 7 depicts an ablation device having one proximal electrode (707) and one distal electrode (709), it should be appreciated that more electrodes can be used in other embodiments. For example, the first electrode (707) may include a set of electrodes (e.g., two or more proximal electrodes). Likewise, the second electrode (709) may include a set of electrodes (e.g., two or more distal electrodes). In some embodiments, a diameter of the electrodes (707, 709) may be between about 1 mm and about 6 mm, including all values and sub-ranges in between. A length of the electrodes (707, 709) (measured along a longitudinal axis of the first and second catheters) may be between about 1 mm and about 8 mm, including all values and sub-ranges in between. In some embodiments, a set of electrodes disposed on a surface of the first catheter (703) (e.g., a set of two or more proximal electrodes (707)) may be spaced apart by between about 0.5 mm and about 9 mm, including all values and sub-ranges in between. In some embodiments, a set of electrodes disposed on a surface of the second catheter (705) (e.g., a set of two or more distal electrodes (709)) may be spaced apart by between about 0.5 mm and about 9 mm, including all values and sub-ranges in between. In some embodiments, the inflatable member (710) in a second configuration (e.g., inflated) may have an outer diameter of between about 20 mm and about 40 mm, including all values and sub-ranges in between. In some embodiments, the inflatable member (710) in a first configuration (e.g., deflated, undeployed state) may have a length (measured along a longitudinal axis of the second catheter) of between about 10 mm and about 80 mm, including all values and sub-ranges in between, when the first and second electrodes (707, 709) are maximally separated. In a fully deployed state with the second catheter (705) retracted for minimal separation between the first and second electrodes (707, 709), a length of the inflatable member (710) (measured along a longitudinal axis of the first catheter (703) may be between about 3 mm and about 30 mm, including all values and sub-ranges in between.

FIG. 8 is a schematic cross-sectional side view of an ablation device (800) (e.g., structurally and/or functionally similar to the ablation device (110, 200, 300, 400, 500, 600, 700)). The ablation device (800) may include a first catheter (803) (e.g., outer catheter shaft) defining a lumen, a second catheter (805) (e.g., an inner shaft defining a guidewire lumen), and an inflatable member (810). The second catheter (805) may be disposed within a lumen of the first catheter (803) and a chamber of the inflatable member (810) where the second catheter (805) may be slidable relative to the first catheter (803). The inflatable member (e.g., balloon) (810) may be coupled to the second catheter (805) such that the second catheter (805) may pass through an inner chamber of the inflatable member (810). A first electrode (807) may be disposed on a surface of a distal portion of the first catheter (803) and just proximal to the inflatable member (810). A second electrode (809) may be disposed on a distal portion (812) of the second catheter (805) and just distal to the inflatable member (810). The second catheter (805) may be linearly slideable relative to the first catheter (803). Thus, the second electrode (809) may be slideable relative to the first electrode (807). A proximal portion of the inflatable member (810) may be coupled to the first catheter (803) and a distal portion of the inflatable member (810) may be coupled to the second catheter (805) such that the second catheter (805) may pass through an inner chamber of the inflatable member (810).

In some embodiments, the ablation device (800) may include a handle (not shown) coupled to a proximal portion of the ablation device (800) and may include a mechanism (not shown) (e.g., knob, switch, pull wires) configured to advance and retract the second catheter (805) such that a distance between the first electrode (807) and the second electrode (809) may be varied. For example, the first electrode (807) and the second electrode (809) may be brought closer together by retracting the second catheter or guidewire (805) relative to the first catheter (803). In FIG. 8, a central portion (813) of a distal end of the inflatable member (810) is shown as retracted toward a proximal end of the inflatable member (810) using a handle and a bending mechanism as described herein.

When suitably inflated, a proximal major portion (815) and a distal major portion (819) of the inflatable member (810) may be gently curved with the surface locally having an angle relative to a longitudinal axis of the first catheter (803) such that a surface of the inflatable member (810) locally forms an angle (831) with respect to the longitudinal axis. In some embodiments, a middle portion (821) of the inflatable member (810) may be relatively short in length compared to the major portions (815, 819). In some embodiments, the major portions (815, 819) may be gently curved with steep slopes with respect to the longitudinal axis (825) of the first catheter (803). In FIG. 8, a local tangent (829) to a surface of the inflatable member (i.e., the component of the local tangent in the plane defined by radial and axial directions) may form an angle (831) with the longitudinal axis (825) that is greater than about 45 degrees.

In some embodiments, a middle portion (821) of the inflatable member (810) may be relatively short in length compared to the major portions (815, 819). When the inflatable member (810) is inflated (e.g., suitably pressurized), the middle portion (821) may bulge as shown in FIG. 8. In some embodiments, the middle portion (821) of the inflatable member (810) may be constructed of thinner material compared to the major portions (815, 819). For example, the thickness of a wall of an inflatable member (810) of the major portions (815, 819) may be at least 20% larger than the thickness of the wall at the middle portion (821). In some embodiments, the thickness of a wall of an inflatable member (810) of the major portions (815, 819) may be at least 50% larger than the thickness of the wall at the middle portion (821). In some embodiments, the thickness of a wall of an inflatable member (810) of the major portions (815, 819) may be at least 100% larger than the thickness of the wall at the middle portion (821).

FIG. 10 is a schematic side view of portion of the wall (1000) of an uninflated inflatable member including a proximal portion (1003), a middle portion (1005), and a distal portion (1007). FIG. 10 illustrates schematically that the thickness (1011) of the proximal portion and thickness (1013) of the distal portion may be significantly larger than the thickness (1012) of the middle portion.

FIG. 11 is a schematic side view of a portion of a wall (1700) of an inflatable member of an ablation device, including a proximal portion (1703), a middle portion (1705), and a distal portion (1707), as arranged along a longitudinal or central axis (1710) of the inflatable member. Any of the inflatable members described herein (e.g., inflatable members 207, 305, 404, 505, 606, etc.) can have a wall that is structurally and/or functionally similar to the wall (1700) depicted in FIG. 11. The proximal portion (1703) of the wall (1700) can have a length L1 extending along the longitudinal axis (1710), the middle portion (1705) of the wall (1700) can have a length L2 extending along the longitudinal axis (1710), and the distal portion (1707) of the wall (1700) can have a length L3 extending along the longitudinal axis (1710). The lengths L1 and L3 can be greater than L2, with the ratios L1/L2 and L3/L2 being greater than three.

As depicted in FIG. 11, the proximal portion (1703) of the wall (1700) of the inflatable member can have a maximum thickness D1, the middle portion (1705) of the wall (1700) can have a minimum thickness D2, and the distal portion (1707) of the wall (1700) can have a maximum thickness D3. In some embodiments, thicknesses D1 and D3 of the proximal and distal portions (1703, 1707), respectively, can be equal to one another (or about equal to one another), and the thickness D2 of the middle portion (1705) can be equal to or less than about a third of the thicknesses D1 and D3.

Although FIG. 8 depicts an ablation device having one proximal electrode (807) and one distal electrode (809), it should be appreciated that more electrodes can be used in other embodiments. For example, the first electrode (807) may include a set of electrodes (e.g., two or more proximal electrodes). Likewise, the second electrode (809) may include a set of electrodes (e.g., two or more distal electrodes). In some embodiments, a diameter of the electrodes (807, 809) may be between about 1 mm and about 6 mm, including all values and sub-ranges in between. A length of the electrodes (807, 809) (measured along a longitudinal axis of the first and second catheters) may be between about 1 mm and about 8 mm, including all values and sub-ranges in between. In some embodiments, a set of electrodes disposed on a surface of the first catheter (803) (e.g., a set of two or more proximal electrodes (807)) may be spaced apart by between about 0.5 mm and about 9 mm, including all values and sub-ranges in between. In some embodiments, a set of electrodes disposed on a surface of the second catheter (805) (e.g., a set of two or more distal electrodes (809)) may be spaced apart by between about 0.5 mm and about 9 mm, including all values and sub-ranges in between. In some embodiments, the inflatable member (810) in a second configuration (e.g., inflated) may have an outer diameter of between about 20 mm and about 40 mm, including all values and sub-ranges in between. In some embodiments, the inflatable member (810) in a first configuration (e.g., deflated, undeployed state) may have a length (measured along a longitudinal axis of the second catheter) of between about 10 mm and about 80 mm, including all values and sub-ranges in between, when the first and second electrodes (807, 809) are maximally separated. In a fully deployed state with the second catheter (805) retracted for minimal separation between the first and second electrodes (807, 809), a length of the inflatable member (810) (measured along a longitudinal axis of the first catheter (803) may be between about 3 mm and about 30 mm, including all values and sub-ranges in between.

FIG. 9 is a perspective view of an ablation device (900) (e.g., structurally and/or functionally similar to the ablation device (110, (801))). In particular, the ablation device (900) corresponds to a perspective view of the ablation device (800) depicted in FIG. 8. The ablation device (900) may include a first catheter (903) (e.g., an outer catheter shaft) defining a lumen, a second catheter (e.g., inner shaft or guidewire lumen) (whose tip (912) is shown), and an inflatable member (910). The second catheter may be disposed within a lumen of the first catheter (903) and a chamber of the inflatable member (910) where the second catheter may be slideable relative to the first catheter (903). The inflatable member (e.g., balloon) (910) may be coupled to the second catheter such that the second catheter may pass through an inner chamber of the inflatable member (910). A first electrode (907) may be disposed on a surface of a distal portion of the first catheter (903) and separated from the inflatable member (910). A second electrode (909) may be disposed on a distal portion (912) of the second catheter and separated from the inflatable member (910). The second catheter may be linearly slideable relative to the first catheter (903). Thus, the second electrode (909) may be slideable relative to the first electrode (907). A proximal portion of the inflatable member (910) may be coupled to the distal portion of the first catheter (903). A proximal major portion (915) and a distal major portion (919) of the inflatable member (910) may be gently curved with the surface locally having an angle relative to a longitudinal axis of the first catheter (903). In some embodiments, a middle portion (921) of the inflatable member (910) may be relatively short in length compared to the major portions (915, 919). In some embodiments, the major portions (915, 919) may be gently curved with steep slopes with respect to a longitudinal axis of the first catheter (903).

FIGS. 12A and 12B depict different views of an ablation device (1800), which can include components that are structurally and/or functionally similar to those of other ablation devices described herein. The ablation device (1800) can include a first electrode (1809) coupled to a proximal end of an inflatable member (1806), and a second electrode (1811) coupled to a distal end of the inflatable member (1806). In some embodiments, the second electrode (1811) can be coupled to an inner catheter or inner shaft or guidewire lumen, which in turn can be attached to a proximal handle (not depicted) for deploying the ablation device (1800). For example, the ablation device (1800) can be deployed by moving (e.g., pulling) the inner shaft proximally such that the second electrode (1811) is pulled toward the first electrode (1809) and the inflatable member (1806) is inflated. Once deployed, the ablation device (1800) can be locked in place with an appropriate locking mechanism, e.g., a locking mechanism disposed in the handle.

The inflatable member (1806) in the inflated and deployed configuration can form a conical shape, such as shown in FIGS. 12A and 12B. In the deployed configuration, which is shown in more detail in FIG. 13, the inflatable member (1806) can have a maximum width W, a height H, and rounded sides (e.g., a side portion) with a radius of curvature R. In some embodiments, e.g., when the inflatable member (1806) is designed for use within a pulmonary vein of a heart, the width W can be less than about 40 mm, the height H can be less than about 25 mm, and the radius R can be less than about 15 mm.

In some embodiments, the first and second electrodes (1809, 1811) can be structurally similar. For example, each of the first and second electrodes (1809, 1811) can have an outer diameter of about 1 mm to about 7 mm and a length of about 1 mm to about 15 mm. In some embodiments, the second electrode (1811) can have a rounded or atraumatic shape, e.g., as depicted in FIG. 14. The inner shaft or guidewire lumen can be used to pass a guidewire through it to assist with engaging a pulmonary vein, so that the catheter can be delivered to the target anatomy over the guidewire.

In some embodiments, a proximal portion of the inflatable member (1806) in the deployed configuration can be angled relative to a longitudinal axis of the ablation device (1800) by an angle A1, and a distal portion of the inflatable member (1806) can be angled relative to the longitudinal axis of the ablation device (1800) by an angle A2. In some embodiments, angle A2 can be greater than angle A1, such that the inflatable member (1806) when deployed has an asymmetrical shape. For example, in some embodiments, angle A1 can lie in the range between about 50 degrees and about 75 degrees, while angle A2 can be between about 80 degrees and about 90 degrees.

FIG. 14 depicts a cross-sectional side view of an ablation device (1900), e.g., including components that are structurally and/or functionally similar to those of other ablation devices described herein, while being disposed in a pulmonary vein ostium (1901) of a heart. In particular, similar to ablation device (1800), ablation device (1900) includes two electrodes (1909, 1911) disposed on opposite sides of an inflatable member (1906). Electrode (1911) disposed at a distal end of the inflatable member (1906) can have a rounded or atraumatic tip (1911a). When deployed, the inflatable member (1906) of the ablation device (1900) can have sides that engage with a wall (1902) of the pulmonary vein ostium (1901) and can hold the ablation device (1900) relative to the pulmonary vein ostium (1901). In the arrangement depicted in FIG. 14, the ablation device (1900) can be held such that its longitudinal axis is generally aligned with a longitudinal axis of the pulmonary vein ostium (1901), with a proximal side of the inflatable member (1906) facing the blood pool (1903) of the heart chamber. Alternatively, the ablation device (1900) can be held at other orientations with respect to the pulmonary vein ostium (1901) and generate different ablation zones within the surrounding tissue.

When oriented as shown in FIG. 14, the electrodes (1909, 1911) can generate an ablation zone (1920) when they are configured as an anode-cathode pair for delivering ablative energy, e.g., via irreversible electroporation as further described herein. The inflatable member (1906) can be formed of an insulating material and, as orientated and shaped, can direct the electric field generated by the electrodes (1909, 1911) toward the wall (1902) of the pulmonary vein ostium (1901).

Each of the ablation devices (110, 200, 300, 400, 500, 600, 700, 800, 900, 1800, 1900, etc.) described herein may include a handle (not shown) that may, in some embodiments, be coupled to a proximal portion of the ablation device and may include a mechanism (not shown) (e.g., knob, switch, pull wires) configured to modify the location of the second electrode relative to the first electrode. For example, the first electrode and the second electrode may be brought closer together by retracting the second catheter or guidewire lumen relative to the first catheter. In some embodiments, the first catheter may have a deflectable portion proximal to the proximal electrode whose shape is controlled by a steering knob or other control on the catheter handle. In embodiments, the device is tracked over a guidewire positioned in a pulmonary vein through a steerable sheath, and deflection of the sheath can provide steering control for positioning the guidewire and inflatable member of the ablation catheter in a pulmonary vein. The inflatable member may be inflated through a fluid port attached to the catheter handle wherein distilled or deionized water can be infused under pressure. In this manner, apposition of the ablation device to tissue may be provided at a desired position and orientation (e.g., at a pulmonary vein ostium).

The ablation devices described herein may be useful for forming lesions on endocardial surfaces, such as an inner surface of a pulmonary vein, as described herein. A distal portion of the inflatable member may include and/or be formed in an atraumatic shape that reduces trauma to tissue (e.g., prevents and/or reduces the possibility of tissue puncture). The inflatable member may be sized for advancement into an endocardial space. A set of electrical leads and/or a fluid (e.g., saline) may be disposed within the lumen of the first catheter.

In some embodiments, the electrodes may be shaped to conform to the shape of the catheter upon which they are disposed. For example, the electrodes may be press fit (e.g., crimped) to a first catheter or outer shaft, or attached using an adhesive with electrical leads attached to the electrodes. The first catheter may include flexible portions (e.g., may be deflectable) to enhance flexibility and allow the device to be deflected.

Each of the electrodes of any of the ablation devices discussed herein may be connected to an insulated electrical lead (not shown) leading to a handle (not shown) coupled to a proximal portion of the first catheter. The insulation on each of the electrical leads may sustain an electrical potential difference of at least 700 V across its thickness without dielectric breakdown. In other embodiments, the insulation on each of the electrical leads may sustain an electrical potential difference of between about 200 V to about 3,000 V across its thickness without dielectric breakdown, including all values and sub-ranges in between. This allows the electrodes and inflatable member coupled thereto to effectively deliver electrical energy and to ablate tissue through irreversible electroporation. The electrodes may, for example, receive pulse waveforms generated by a signal generator (122) as discussed above with respect to FIG. 1.

For each of the ablation devices discussed herein, the electrodes may include biocompatible metals such as titanium, palladium, gold, silver, platinum or a platinum alloy. For example, the electrode may preferably include platinum or a platinum alloy. In some embodiments, the proximal electrodes may have a biocompatible coating that permits capacitive voltage delivery with biphasic waveforms. Each electrode may include an electrical lead having sufficient electrical insulation to sustain an electrical potential difference of at least 700 V across its thickness without dielectric breakdown. In other embodiments, the insulation on each of the electrical leads may sustain an electrical potential difference of between about 200 V to about 3,000 V across its thickness without dielectric breakdown, including all values and sub-ranges in between. The insulated electrical leads may run to the proximal handle portion of the ablation device from where they may be connected to a suitable electrical connector. The first catheter may be made of a flexible polymeric material such as Teflon, Nylon, Pebax, etc.

In some embodiments, the inflatable members as described herein may have an expandable structure and may be composed of any of a variety of insulating or dielectric materials including, but not limited to polyvinyl chloride (PVC), polyethylene (PE), cross-linked polyethylene, polyolefins, polyolefin copolymer (POC), polyethylene terephthalate (PET), polyester, nylon, polymer blends, polyester, polyimide, polyamides, polyurethane, silicone, polydimethylsiloxane (PDMS), PEBAX, and the like. Preferred embodiments can be composed of polyurethane or silicone. Together with the use of distilled or deionized water to inflate the inflatable member, the inflatable member serves as an effective insulator during delivery of the Pulsed Electric Field waveform and drives the electric field to the region outside the inflatable member or balloon and surrounding the balloon.

II. Methods

Also described here are methods for ablating tissue in a pulmonary vein (e.g., pulmonary vein in the left atrium) using the systems and devices described above. Generally, the methods described here include introducing and disposing a device in an ostium of a pulmonary vein. A pulse waveform may be delivered by one or more electrodes and an inflatable member (e.g., balloon) of the device to ablate tissue. In some embodiments, a cardiac pacing signal may synchronize the delivered pulse waveforms with the cardiac cycle. Additionally or alternatively, the pulse waveforms may include a plurality of levels of a hierarchy to reduce total energy delivery. The tissue ablation thus performed may be delivered in synchrony with paced heartbeats and with less energy delivery to reduce damage to healthy tissue. It should be appreciated that any of the ablation devices described herein may be used to ablate tissue using the methods discussed below as appropriate.

Generally, and as illustrated in FIGS. 20A-20B, a method (1600) includes the introduction of a device (e.g., ablation device, such as the ablation devices (110, 200, 300, 400, 500, 600, 700, 800, 900) into an endocardial space of a pulmonary vein. The ablation device may be introduced in a first or deflated configuration and transitioned to a second or inflated configuration in an ostium of a pulmonary vein. Once positioned, voltage pulse waveforms may be applied to tissue during a refractory period of the cardiac cycle. Electrophysiology data of the cardiac chamber may be recorded to determine efficacy of the ablation.

The method (1600) may begin with creating an access site in a patient (1602). For example, a first access site may be via a femoral vein of the patient. A guidewire may be advanced into the access site via the femoral vein and into the right atrium of the patient (1604). A dilator and a deflectable sheath may be advanced over the guidewire and into the right atrium (1606). The sheath may, for example, be configured for deflecting up to about 180 degrees or more. The dilator may be advanced from the right atrium into the left atrium through the septum (1608) to create a transseptal opening. For example, the dilator may be advanced from the right atrium into the left atrium through the interatrial septum to create the transseptal opening. The interatrial septum may include the fossa ovalis of the patient. The transseptal opening may be dilated using the dilator (1610). For example, the dilator may be advanced out of the sheath and used to puncture the fossa ovalis to create the transseptal opening (assuming the patient is heparinized). Alternatively, a transseptal needle (e.g., Brockenbrough needle) may be used to create the transseptal opening. The sheath may be advanced from the right atrium into the left atrium (1612) through the transseptal opening. An ablation device may be advanced into the left atrium over the guidewire (1614), with the second catheter or guidewire lumen of the ablation device tracking over the guidewire.

In some embodiments, the ablation device may include a catheter lumen and a set of insulated electrical leads extending through the lumen. In embodiments, a thin microcatheter with a circular distal shape with electrodes mounted on the circular shape may be introduced through the second catheter or guidewire lumen into the pulmonary vein, and used to record intracardiac ECG data to confirm successful ablation.

Still referring to FIGS. 20A-20B, a second access site may be created in the patient to advance a lead or catheter for cardiac stimulation into the patient's heart. For example, the second access site may be via a jugular vein of the patient. The device for cardiac stimulation may be advanced into the right ventricle through the second access site (1620) (e.g., near the apex of the right ventricle). A pacing signal may be generated by a cardiac stimulator and applied to the heart for cardiac stimulation of the heart. An indication of the pacing signal may be transmitted from the cardiac stimulator to the signal generator. In some embodiments, the operator may confirm the pacing capture and determine that the ventricle is responding to the pacing signal as intended. For example, pacing capture may be confirmed on an ECG display on a signal generator. Confirmation of pacing capture is a safety feature in that ablation is delivered in synchrony with pacing through enforced periodicity of a Q-wave through pacing. Likewise, in some embodiments, an additional pacing catheter may be used for example to pace the right atrium in addition to the right ventricle, and ablation can be delivered during the common refractory window of both cardiac chambers.

The ablation device may be advanced towards a target pulmonary vein (1622) for delivering a pulse waveform configured for tissue ablation. In particular, the ablation device in the second configuration may be advanced towards a pulmonary vein of the heart to engage tissue surface. The sheath may be deflected as needed to direct the ablation device towards the target vein. The inflatable member may be transitioned to a second configuration where the inflatable member inflates to contact the inflatable member against the pulmonary vein. Once the ablation device is in position within the heart to deliver one or more pulse waveforms, an extension cable may be used to electrically couple a signal generator to a proximal end of the handle of the ablation device. After pacing the right ventricle using the pacing device (1624), the pulse waveform may be delivered to the target site using the ablation device to ablate tissue. The pulse waveform may be delivered in synchronization with the pacing signal.

While examples of ablation devices configured for delivery of irreversible electroporation pulsed electric field therapy have been described here, the examples described herein are provided for exemplary purposes only and those skilled in the art may devise other variations without departing from the scope of the present invention. For example, a range and variety of materials, polyhedral sides, electrode diameters, device dimensions, voltage levels, proximal electrodes, and other such details are possible and may be implemented as convenient for the application at hand without departing from the scope of the present invention. In embodiments where the distal shaft of the catheter is deflectable, the catheter shaft may undergo a range of deflections by controlling deflection from a catheter handle.

As discussed herein, the pulse waveform may be generated by a signal generator coupled to the ablation device. The signal generator may be electrically coupled to a proximal end of a handle of the ablation device. For example, an extension cable may electrically couple the signal generator to the proximal end of the handle. In some embodiments, the pulse waveform may include a time offset with respect to the pacing signal. In some embodiments, the pulse waveform may include a first level of a hierarchy of the pulse waveform including a first set of pulses. Each pulse has a pulse time duration and a first time interval separating successive pulses. A second level of the hierarchy of the pulse waveform may include a plurality of first sets of pulses as a second set of pulses. A second time interval may separate successive first sets of pulses. The second time interval may be at least three times the duration of the first time interval. A third level of the hierarchy of the pulse waveform may include a plurality of second sets of pulses as a third set of pulses. A third time interval may separate successive second sets of pulses. The third time interval may be at least thirty times the duration of the second level time interval. A fourth level of the hierarchy of the pulse waveform may include a plurality of third sets of pulses as a fourth set of pulses. A fourth time interval may separate successive third sets of pulses. The fourth time interval may be at least ten times the duration of the third level time interval.

In other embodiments, the ablation device may be withdrawn from the heart over the guidewire and a mapping catheter may be advanced over the guidewire to record the post-ablation electrophysiology data of the target site. If the ablation is not successful (1630—NO) based on the electrophysiology data and predetermined criteria, then the process may return to step 1626 for delivery of additional pulse waveforms. The pulse waveform parameters may be the same or changed for subsequent ablation cycles.

If analysis of the electrophysiology data indicates that the ablation is successful (e.g., tissue portion is electrically silent) (1630—YES), then a determination may be made of other target portions to ablate (1632) (e.g., other pulmonary veins). Another target portion may be selected (1624) and the process may return to step 1622 when other portions are to be ablated. When switching between target tissue, the inflatable member may be at least partially deflated, and the ablation device may be advanced towards another portion of tissue. If no other portions are to be ablated (1632—NO), the ablation device, pacing catheters, sheath, guidewire, and the like, may be removed from the patient (1636).

It should be noted that for any of the steps described herein, a radiopaque portion of the ablation device may be fluoroscopically imaged to aid an operator. For example, visual confirmation may be performed through fluoroscopic imaging that the inflatable members in the second configuration is in contact with and approximately centered in a vein, by means of a radio-opaque marker band placed on the distal portion of the device.

It should be understood that the examples and illustrations in this disclosure serve exemplary purposes and departures and variations such as inflatable member characteristics, number of electrodes, and so on can be built and deployed according to the teachings herein without departing from the scope of this invention.

Pulse Waveform

Disclosed herein are methods, systems and apparatuses for the selective and rapid application of pulsed electric fields/waveforms to effect tissue ablation with irreversible electroporation. The pulse waveform(s) as disclosed herein are usable with any of the systems (100), devices (e.g., 200, 300, 400, 500, 600, 700, 800, 900), and methods (e.g., 1600) described herein. Some embodiments are directed to pulsed high voltage waveforms together with a sequenced delivery scheme for delivering energy to tissue via sets of electrodes. In some embodiments, peak electric field values can be reduced and/or minimized while at the same time sufficiently large electric field magnitudes can be maintained in regions where tissue ablation is desired. In some embodiments, a system useful for irreversible electroporation includes a signal generator and a processor capable of being configured to apply pulsed voltage waveforms to a selected plurality or a subset of electrodes of an ablation device. In some embodiments, the processor is configured to control inputs whereby selected pairs of anode-cathode subsets of electrodes can be either simultaneously or sequentially triggered based on a pre-determined sequence, and in one embodiment the sequenced delivery can be triggered from a cardiac stimulator and/or pacing device. In some embodiments, the ablation pulse waveforms are applied in a refractory period of the cardiac cycle so as to avoid disruption of the sinus rhythm of the heart. One example method of enforcing this is to electrically pace the heart with a cardiac stimulator and ensure pacing capture to establish periodicity and predictability of the cardiac cycle, and then to define a time window well within the refractory period of this periodic cycle within which the ablation waveform is delivered.

In some embodiments, the pulsed voltage waveforms disclosed herein are hierarchical in organization and have a nested structure. In some embodiments, the pulsed waveform includes hierarchical groupings of pulses with a variety of associated timescales. Furthermore, the associated timescales and pulse widths, and the numbers of pulses and hierarchical groupings, can be selected so as to satisfy one or more of a set of Diophantine inequalities involving the frequency of cardiac pacing.

Pulsed waveforms for electroporation energy delivery as disclosed herein may enhance the safety, efficiency and effectiveness of the energy delivery by reducing the electric field threshold associated with irreversible electroporation, yielding more effective ablative lesions with reduced total energy delivered.

FIG. 15 illustrates a pulsed voltage waveform in the form of a sequence of rectangular double pulses, with each pulse, such as the pulse (1100) being associated with a pulse width or duration. The pulse width/duration can be about 0.5 microseconds, about 1 microsecond, about 5 microseconds, about 10 microseconds, about 25 microseconds, about 50 microseconds, about 100 microseconds, about 125 microseconds, about 140 microseconds, about 150 microseconds, including all values and sub-ranges in between. The pulsed waveform of FIG. 15 illustrates a set of monophasic pulses where the polarities of all the pulses are the same (all positive in FIG. 15, as measured from a zero baseline). In some embodiments, such as for irreversible electroporation applications, the height of each pulse (1100) or the voltage amplitude of the pulse (1100) can be in the range from about 400 volts, about 1,000 volts, about 5,000 volts, about 10,000 volts, about 15,000 volts, including all values and sub ranges in between. As illustrated in FIG. 15, the pulse (1100) is separated from a neighboring pulse by a time interval (1102), also sometimes referred to as a first time interval. As examples, the first time interval can be about 1 microsecond, about 50 microseconds, about 100 microseconds, about 200 microseconds, about 500 microseconds, about 800 microseconds, about 1 millisecond including all values and sub ranges in between, in order to generate irreversible electroporation.

FIG. 16 introduces a pulse waveform with the structure of a hierarchy of nested pulses. FIG. 16 shows a series of monophasic pulses such as pulse (1200) with pulse width/pulse time duration w, separated by a time interval (also sometimes referred to as a first time interval) such as (1202) of duration t1 between successive pulses, a number m1 of which are arranged to form a group of pulses (1210) (also sometimes referred to as a first set of pulses). Furthermore, the waveform has a number m2 of such groups of pulses (also sometimes referred to as a second set of pulses) separated by a time interval (1212) (also sometimes referred to as a second time interval) of duration t2 between successive groups. The collection of m2 such pulse groups, marked by (1220) in FIG. 16, constitutes the next level of the hierarchy, which can be referred to as a packet and/or as a third set of pulses. The pulse width and the time interval t1 between pulses can both be in the range of microseconds to hundreds of microseconds, including all values and sub ranges in between. In some embodiments, the time interval t2 can be at least three times larger than the time interval t1. In some embodiments, the ratio t2/t1 can be in the range between about 3 and about 300, including all values and sub-ranges in between.

FIG. 17 further elaborates the structure of a nested pulse hierarchy waveform. In this figure, a series of m1 pulses (individual pulses not shown) form a group of pulses (1300) (e.g., a first set of pulses). A series of m2 such groups separated by an inter-group time interval (1310) of duration t2 (e.g., a second time interval) between one group and the next form a packet (e.g., a second set of pulses). A series of m3 such packets separated by time intervals (1312) of duration t3 (e.g., a third time interval) between one packet and the next form the next level in the hierarchy, a super-packet labeled (1320) (e.g., a third set of pulses) in the figure. In some embodiments, the time interval t3 can be at least about thirty times larger than the time interval t2. In some embodiments, the time interval t3 can be at least fifty times larger than the time interval t2. In some embodiments, the ratio t3/t2 can be in the range between about 30 and about 800, including all values and sub-ranges in between. The amplitude of the individual voltage pulses in the pulse hierarchy can be anywhere in the range from 500 volts to 7,000 volts or higher, including all values and sub ranges in between.

FIG. 18 provides an example of a biphasic waveform sequence with a hierarchical structure. In the example shown in the figure, biphasic pulses such as (1400) have a positive voltage portion as well as a negative voltage portion to complete one cycle of the pulse. There is a time delay (1402) (e.g., a first time interval) between adjacent cycles of duration t1, and n1 such cycles form a group of pulses (1410) (e.g., a first set of pulses). A series of n2 such groups separated by an inter-group time interval (1412) (e.g., a second time interval) of duration t2 between one group and the next form a packet (1420) (e.g., a second set of pulses). The figure also shows a second packet (1430), with a time delay (1432) (e.g., a third time interval) of duration t3 between the packets. Just as for monophasic pulses, higher levels of the hierarchical structure can be formed as well. The amplitude of each pulse or the voltage amplitude of the biphasic pulse can be anywhere in the range from 500 volts to 7,000 volts or higher, including all values and sub ranges in between. The pulse width/pulse time duration can be in the range from nanoseconds or even sub-nanoseconds to tens of microseconds, while the delays t1 can be in the range from zero to several microseconds. The inter-group time interval t2 can be at least ten times larger than the pulse width. In some embodiments, the time interval t3 can be at least about twenty times larger than the time interval t2. In some embodiments, the time interval t3 can be at least fifty times larger than the time interval t2.

Embodiments disclosed herein include waveforms structured as hierarchical waveforms that include waveform elements/pulses at various levels of the hierarchy. The individual pulses such as (1200) in FIG. 16 comprise the first level of the hierarchy, and have an associated pulse time duration and a first time interval between successive pulses. A set of pulses, or elements of the first level structure, form a second level of the hierarchy such as the group of pulses/second set of pulses (1210) in FIG. 16. Among other parameters, associated with the waveform are parameters such as a total time duration of the second set of pulses (not shown), a total number of first level elements/first set of pulses, and second time intervals between successive first level elements that describe the second level structure/second set of pulses. In some embodiments, the total time duration of the second set of pulses can be between about 20 microseconds and about 10 milliseconds, including all values and subranges in between. A set of groups, second set of pulses, or elements of the second level structure, form a third level of the hierarchy such as the packet of groups/third set of pulses (1220) in FIG. 16. Among other parameters, there is a total time duration of the third set of pulses (not shown), a total number of second level elements/second set of pulses, and third time intervals between successive second level elements that describe the third level structure/third set of pulses. The generally iterative or nested structure of the waveforms can continue to a higher plurality of levels, such as ten levels of structure, or more.

For example, a pulse waveform may include a fourth level of the hierarchy of the pulse waveform may include a plurality of third sets of pulses as a fourth set of pulses, a fourth time interval separating successive third sets of pulses, the fourth time interval being at least ten times the duration of the third level time interval.

In some embodiments, hierarchical waveforms with a nested structure and hierarchy of time intervals as described herein are useful for irreversible electroporation ablation energy delivery, providing a good degree of control and selectivity for applications in different tissue types. A variety of hierarchical waveforms can be generated with a suitable pulse generator. It is understood that while the examples herein identify separate monophasic and biphasic waveforms for clarity, it should be noted that combination waveforms, where some portions of the waveform hierarchy are monophasic while other portions are biphasic, can also be generated/implemented.

In some embodiments, the ablation pulse waveforms described herein are applied during the refractory period of the cardiac cycle so as to avoid disruption of the sinus rhythm of the heart. In some embodiments, a method of treatment includes electrically pacing the heart with a cardiac stimulator to ensure pacing capture to establish periodicity and predictability of the cardiac cycle, and then defining a time window within the refractory period of the cardiac cycle within which one or more pulsed ablation waveforms can be delivered. FIG. 19 illustrates an example where both atrial and ventricular pacing is applied (for instance, with pacing leads or catheters situated in the right atrium and right ventricle respectively). With time represented on the horizontal axis, FIG. 19 illustrates a series of ventricular pacing signals such as (1500) and (1510), and a series of atrial pacing signals (1520, 1530), along with a series of ECG waveforms (1540, 1542) that are driven by the pacing signals. As indicated in FIG. 19 by the thick arrows, there is an atrial refractory time window (1522) and a ventricular refractory time window (1502) that respectively follow the atrial pacing signal (1522) and the ventricular pacing signal (1500). As shown in FIG. 19, a common refractory time window (1550) of duration Tr can be defined that lies within both atrial and ventricular refractory time windows (1522, 1502). In some embodiments, the electroporation ablation waveform(s) can be applied in this common refractory time window (1550). The start of this refractory time window (1522) is offset from the pacing signal (1500) by a time offset (1504) as indicated in FIG. 19. The time offset (1504) can be smaller than about 25 milliseconds, in some embodiments. At the next heartbeat, a similarly defined common refractory time window (1552) is the next time window available for application of the ablation waveform(s). In this manner, the ablation waveform(s) may be applied over a series of heartbeats, at each heartbeat remaining within the common refractory time window. In one embodiment, each packet of pulses as defined above in the pulse waveform hierarchy can be applied over a heartbeat, so that a series of packets is applied over a series of heartbeats, for a given electrode set.

As used herein, the terms “about” and/or “approximately” when used in conjunction with numerical values and/or ranges generally refer to those numerical values and/or ranges near to a recited numerical value and/or range. In some instances, the terms “about” and “approximately” may mean within ±10% of the recited value. For example, in some instances, “about 100 [units]” may mean within ±10% of 100 (e.g., from 90 to 110). The terms “about” and “approximately” may be used interchangeably.

Some embodiments described herein relate to a computer storage product with a non-transitory computer-readable medium (also may be referred to as a non-transitory processor-readable medium) having instructions or computer code thereon for performing various computer-implemented operations. The computer-readable medium (or processor-readable medium) is non-transitory in the sense that it does not include transitory propagating signals per se (e.g., a propagating electromagnetic wave carrying information on a transmission medium such as space or a cable). The media and computer code (also may be referred to as code or algorithm) may be those designed and constructed for the specific purpose or purposes. Examples of non-transitory computer-readable media include, but are not limited to, magnetic storage media such as hard disks, floppy disks, and magnetic tape; optical storage media such as Compact Disc/Digital Video Discs (CD/DVDs), Compact Disc-Read Only Memories (CD-ROMs), and holographic devices; magneto-optical storage media such as optical disks; carrier wave signal processing modules; and hardware devices that are specially configured to store and execute program code, such as Application-Specific Integrated Circuits (ASICs), Programmable Logic Devices (PLDs), Read-Only Memory (ROM) and Random-Access Memory (RAM) devices. Other embodiments described herein relate to a computer program product, which may include, for example, the instructions and/or computer code disclosed herein.

The systems, devices, and/or methods described herein may be performed by software (executed on hardware), hardware, or a combination thereof. Hardware modules may include, for example, a general-purpose processor (or microprocessor or microcontroller), a field programmable gate array (FPGA), and/or an application specific integrated circuit (ASIC). Software modules (executed on hardware) may be expressed in a variety of software languages (e.g., computer code), including C, C++, Java®, Ruby, Visual Basic®, and/or other object-oriented, procedural, or other programming language and development tools. Examples of computer code include, but are not limited to, micro-code or micro-instructions, machine instructions, such as produced by a compiler, code used to produce a web service, and files containing higher-level instructions that are executed by a computer using an interpreter. Additional examples of computer code include, but are not limited to, control signals, encrypted code, and compressed code.

The specific examples and descriptions herein are exemplary in nature and embodiments may be developed by those skilled in the art based on the material taught herein without departing from the scope of the present invention, which is limited only by the attached claims.

Claims

1. An apparatus, comprising: a first shaft having a longitudinal axis and defining a lumen;a second shaft disposed within the lumen and having a distal portion that extends from a distal portion of the first shaft, the second shaft moveable along the longitudinal axis relative to the first shaft;a first electrode coupled to the distal portion of the first shaft;a second electrode coupled to the distal portion of the second shaft, the first and second electrodes configured to generate an electric field for ablating tissue; andan inflatable member disposed between the first and second electrodes, the inflatable member configured to transition from an undeployed configuration to a deployed configuration in response to the second shaft being moved proximally relative to the first shaft, the inflatable member in the deployed configuration configured to engage a wall of a pulmonary vein ostium and direct the electric field generated by the first and second electrodes toward the wall.
2. The apparatus of claim 1, wherein the inflatable member in the deployed configuration includes at least a proximal portion or a distal portion that is angled greater than about 45 degrees relative to the longitudinal axis.
3. The apparatus of claim 1, wherein the inflatable member includes a wall having: a proximal portion;a distal portion; anda middle portion disposed between the proximal and distal portions of the wall, the middle portion having a minimum thickness that is less than a thickness of the proximal and distal portions of the wall.
4. The apparatus of claim 3, wherein a length of each of the proximal and distal portions of the inflatable member along the longitudinal axis is greater than a length of the middle portion along the longitudinal axis.
5. The apparatus of claim 4, wherein a ratio of the length of the proximal portion to the length of the middle portion and a ratio of the length of the distal portion to the length of the middle portion are greater than about three.
6. The apparatus of claim 1, wherein the inflatable member in the deployed configuration has a cross-sectional shape having a width of less than about 40 mm, a height of less than about 25 mm, and a side portion with a radius of curvature of less than about 15 mm.
7. The apparatus of claim 1, wherein the inflatable member in the deployed configuration has a cross-sectional shape having a maximum width of between about 20 mm and about 40 mm.
8. The apparatus of claim 1, wherein the first electrode is attached to a proximal portion of the inflatable member and the second electrode is attached to a distal portion of the inflatable member.
9. The apparatus of claim 1, wherein each of the first and second electrodes has an outer diameter of about 1 mm to 7 mm and a length along the longitudinal axis of about 1 mm to about 15 mm.
10. The apparatus of claim 1, wherein the second electrode has a rounded distal end.
11. An apparatus, comprising: a shaft having a longitudinal axis and defining a lumen;an inflatable member disposed near a distal portion of the shaft, the inflatable member configured to transition between an undeployed configuration and a deployed configuration, the inflatable member including a wall having a proximal portion, a distal portion, and a middle portion disposed between the proximal and distal portions of the wall, the middle portion having a minimum thickness that is less than a thickness of the proximal and distal portions of the wall; andfirst and second electrodes disposed on opposite sides of the inflatable member along the longitudinal axis, the first and second electrodes configured to generate an electric field for ablating tissue.
12. The apparatus of claim 11, wherein the inflatable member in the deployed configuration includes at least a proximal portion or a distal portion that is angled greater than about 45 degrees relative to the longitudinal axis.
13. The apparatus of claim 11, wherein the inflatable member in the deployed configuration is configured to engage a wall of a pulmonary vein ostium, the inflatable member formed of an insulating material such that the inflatable member in the deployed configuration directs the electric field generated by the first and second electrodes toward the wall of the pulmonary vein ostium.
14. The apparatus of claim 11, wherein the minimum thickness of the middle portion is less than about a third of the thickness of at least the proximal or distal portion of the wall.
15. The apparatus of claim 11, wherein a length of each of the proximal and distal portions of the inflatable member along the longitudinal axis is greater than a length of the middle portion along the longitudinal axis.
16. The apparatus of claim 15, wherein a ratio of the length of the proximal portion to the length of the middle portion and a ratio of the length of the distal portion to the length of the middle portion are greater than about three.
17. The apparatus of claim 11, wherein the inflatable member in the deployed configuration has a cross-sectional shape having a width of less than about 40 mm, a height of less than about 25 mm, and a side portion with a radius of curvature of less than about 15 mm.
18. The apparatus of claim 11, wherein the inflatable member is fluidically coupled to an infusion device, the inflatable member configured to transition from the undeployed configuration to the deployed configuration in response to an infusion of fluid from the infusion device.
19. The apparatus of claim 18, wherein the infusion of fluid is delivered at an infusion pressure of between about 2 psi and about 20 psi.
20. A system, comprising: a signal generator configured to generate a pulse waveform;an ablation device coupled to the signal generator, the ablation device including: first and second electrodes configured to receive the pulse waveform and generate an electric field for ablation; andan inflatable member formed of an insulating material and disposed between the first and second electrodes, the inflatable member configured to transition between an undeployed configuration in which the inflatable member can be advanced to a pulmonary vein ostium to a deployed configuration in which the inflatable member can engage with a wall of the pulmonary vein ostium, the inflatable member in the deployed configuration configured to direct the electric field toward the wall.
21. The system of claim 20, wherein the ablation device further includes: a first shaft having a longitudinal axis and defining a lumen; anda second shaft extending through the lumen, the second shaft movable relative to the first shaft to bring proximal and distal ends of the inflatable member along the longitudinal axis closer to one another to transition the inflatable member from the undeployed state into the deployed state.
22. The system of claim 21, further comprising a handle coupled to a proximal portion of the ablation device, the handle including a mechanism configured to move the second shaft relative to the first shaft.
23. The system of claim 22, wherein the handle further includes a locking mechanism configured to lock a position of the second shaft relative to the first shaft to maintain the inflatable member in the deployed configuration.
24. The system of claim 20, further comprising an infusion device configured to pressurize the inflatable member to transition the inflatable member from the undeployed configuration to the deployed configuration.
25. The system of claim 20, wherein the inflatable member in the deployed configuration has a cross-sectional shape having a width of less than about 40 mm, a height of less than about 25 mm, and a side portion with a radius of curvature of less than about 15 mm.
26. A method, comprising: retracting an inner shaft of an ablation device relative to an outer shaft of the ablation device, the inner shaft disposed within a lumen of the outer shaft;transitioning, in response to retracting the inner shaft relative to the outer shaft, an inflatable member of the ablation device from an undeployed configuration to a deployed configuration in which a side portion of the inflatable member engages a wall of a pulmonary vein ostium; anddelivering, after the transitioning, a pulse waveform to first and second electrodes of the ablation device such that the first and second electrodes generate an electric field for ablating the wall of the pulmonary vein ostium, the first and second electrodes disposed on opposite sides of the inflatable member.
27. The method of claim 26, wherein the inflatable member is formed from an insulating material such that the inflatable member is configured to direct the electric field generated by the first and second electrodes toward the wall of the pulmonary vein ostium.
28. The method of claim 26, further comprising locking, after the retracting, a position of the inner shaft relative to the outer shaft using a locking mechanism of the ablation device.
29. The method of claim 26, further comprising deflecting, prior to the retracting, a portion of the inner shaft to position the inflatable member in the pulmonary vein ostium.
30. The method of claim 26, further comprising infusing the inflatable member with a fluid.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/734,214, filed on Sep. 20, 2018, the entire disclosure of which is incorporated herein by reference in its entirety.

US Referenced Citations (684)

Number	Name	Date	Kind
4200104	Harris	Apr 1980	A
4470407	Hussein	Sep 1984	A
4739759	Rexroth et al.	Apr 1988	A
5234004	Hascoet et al.	Aug 1993	A
5242441	Avitall	Sep 1993	A
5257635	Langberg	Nov 1993	A
5281213	Milder et al.	Jan 1994	A
5304214	DeFord et al.	Apr 1994	A
5306296	Wright et al.	Apr 1994	A
5334193	Nardella	Aug 1994	A
5341807	Nardella	Aug 1994	A
5342301	Saab	Aug 1994	A
5398683	Edwards et al.	Mar 1995	A
5443463	Stern et al.	Aug 1995	A
5454370	Avitall	Oct 1995	A
5515848	Corbett, III et al.	May 1996	A
5531685	Hemmer et al.	Jul 1996	A
5545161	Imran	Aug 1996	A
5578040	Smith	Nov 1996	A
5617854	Munsif	Apr 1997	A
5624430	Eton et al.	Apr 1997	A
5667491	Pliquett et al.	Sep 1997	A
5672170	Cho	Sep 1997	A
5700243	Narciso, Jr.	Dec 1997	A
5702438	Avitall	Dec 1997	A
5706823	Wodlinger	Jan 1998	A
5722400	Ockuly et al.	Mar 1998	A
5722402	Swanson et al.	Mar 1998	A
5749914	Janssen	May 1998	A
5779699	Lipson	Jul 1998	A
5788692	Campbell et al.	Aug 1998	A
5810762	Hofmann	Sep 1998	A
5833710	Jacobson	Nov 1998	A
5836874	Swanson et al.	Nov 1998	A
5836942	Netherly et al.	Nov 1998	A
5836947	Fleischman et al.	Nov 1998	A
5843154	Osypka	Dec 1998	A
5849028	Chen	Dec 1998	A
5860974	Abele	Jan 1999	A
5863291	Schaer	Jan 1999	A
5868736	Swanson et al.	Feb 1999	A
5871523	Fleischman et al.	Feb 1999	A
5876336	Swanson et al.	Mar 1999	A
5885278	Fleischman et al.	Mar 1999	A
5895404	Ruiz	Apr 1999	A
5899917	Edwards et al.	May 1999	A
5904709	Arndt et al.	May 1999	A
5916158	Webster, Jr.	Jun 1999	A
5916213	Haissaguerre et al.	Jun 1999	A
5921924	Avitall	Jul 1999	A
5928269	Alt	Jul 1999	A
5928270	Ramsey, III	Jul 1999	A
5938660	Swartz	Aug 1999	A
6002955	Willems et al.	Dec 1999	A
6006131	Cooper et al.	Dec 1999	A
6009351	Flachman	Dec 1999	A
6014579	Pomeranz et al.	Jan 2000	A
6029671	Stevens et al.	Feb 2000	A
6033403	Tu et al.	Mar 2000	A
6035238	Ingle et al.	Mar 2000	A
6045550	Simpson et al.	Apr 2000	A
6068653	LaFontaine	May 2000	A
6071274	Thompson et al.	Jun 2000	A
6071281	Burnside et al.	Jun 2000	A
6074389	Levine et al.	Jun 2000	A
6076012	Swanson et al.	Jun 2000	A
6090104	Webster, Jr.	Jul 2000	A
6096036	Bowe et al.	Aug 2000	A
6113595	Muntermann	Sep 2000	A
6119041	Pomeranz et al.	Sep 2000	A
6120500	Bednarek et al.	Sep 2000	A
6142993	Whayne et al.	Nov 2000	A
6146381	Bowe et al.	Nov 2000	A
6164283	Lesh	Dec 2000	A
6167291	Barajas et al.	Dec 2000	A
6171305	Sherman	Jan 2001	B1
6216034	Hofmann et al.	Apr 2001	B1
6219582	Hofstad et al.	Apr 2001	B1
6223085	Dann et al.	Apr 2001	B1
6231518	Grabek et al.	May 2001	B1
6245064	Lesh et al.	Jun 2001	B1
6251107	Schaer	Jun 2001	B1
6251109	Hassett	Jun 2001	B1
6251128	Knopp et al.	Jun 2001	B1
6270476	Santoianni et al.	Aug 2001	B1
6272384	Simon et al.	Aug 2001	B1
6287306	Kroll et al.	Sep 2001	B1
6314963	Vaska et al.	Nov 2001	B1
6322559	Daulton et al.	Nov 2001	B1
6350263	Wetzig et al.	Feb 2002	B1
6370412	Armoundas et al.	Apr 2002	B1
6391024	Sun et al.	May 2002	B1
6447505	McGovern et al.	Sep 2002	B2
6464699	Swanson	Oct 2002	B1
6470211	Ideker et al.	Oct 2002	B1
6502576	Lesh	Jan 2003	B1
6503247	Swartz et al.	Jan 2003	B2
6517534	McGovern et al.	Feb 2003	B1
6527724	Fenici	Mar 2003	B1
6527767	Wang et al.	Mar 2003	B2
6592581	Bowe	Jul 2003	B2
6595991	Tollner et al.	Jul 2003	B2
6607520	Keane	Aug 2003	B2
6623480	Kuo et al.	Sep 2003	B1
6638278	Falwell et al.	Oct 2003	B2
6666863	Wentzel et al.	Dec 2003	B2
6669693	Friedman	Dec 2003	B2
6702811	Stewart et al.	Mar 2004	B2
6719756	Muntermann	Apr 2004	B1
6723092	Brown et al.	Apr 2004	B2
6728563	Rashidi	Apr 2004	B2
6743225	Sanchez et al.	Jun 2004	B2
6743226	Cosman et al.	Jun 2004	B2
6743239	Kuehn et al.	Jun 2004	B1
6764486	Natale	Jul 2004	B2
6780181	Kroll et al.	Aug 2004	B2
6805128	Pless	Oct 2004	B1
6807447	Griffin, III	Oct 2004	B2
6892091	Ben-Haim et al.	May 2005	B1
6893438	Hall et al.	May 2005	B2
6926714	Sra	Aug 2005	B1
6955173	Lesh	Oct 2005	B2
6960206	Keane	Nov 2005	B2
6960207	Vanney et al.	Nov 2005	B2
6972016	Hill, III et al.	Dec 2005	B2
6973339	Govari	Dec 2005	B2
6979331	Hintringer et al.	Dec 2005	B2
6984232	Vanney et al.	Jan 2006	B2
6985776	Kane et al.	Jan 2006	B2
7001383	Keidar	Feb 2006	B2
7041095	Wang et al.	May 2006	B2
7113831	Hooven	Sep 2006	B2
7171263	Darvish et al.	Jan 2007	B2
7182725	Bonan et al.	Feb 2007	B2
7195628	Falkenberg	Mar 2007	B2
7207988	Leckrone et al.	Apr 2007	B2
7207989	Pike, Jr. et al.	Apr 2007	B2
7229402	Diaz et al.	Jun 2007	B2
7229437	Johnson et al.	Jun 2007	B2
7250049	Roop et al.	Jul 2007	B2
7285116	de la Rama et al.	Oct 2007	B2
7285119	Stewart et al.	Oct 2007	B2
7326208	Vanney et al.	Feb 2008	B2
7346379	Eng et al.	Mar 2008	B2
7367974	Haemmerich et al.	May 2008	B2
7374567	Heuser	May 2008	B2
7387629	Vanney et al.	Jun 2008	B2
7387630	Mest	Jun 2008	B2
7387636	Cohn et al.	Jun 2008	B2
7416552	Paul et al.	Aug 2008	B2
7419477	Simpson et al.	Sep 2008	B2
7419489	Vanney et al.	Sep 2008	B2
7422591	Phan	Sep 2008	B2
7429261	Kunis et al.	Sep 2008	B2
7435248	Taimisto et al.	Oct 2008	B2
7513896	Orszulak	Apr 2009	B2
7527625	Knight et al.	May 2009	B2
7578816	Boveja et al.	Aug 2009	B2
7588567	Boveja et al.	Sep 2009	B2
7623899	Worley et al.	Nov 2009	B2
7678108	Chrisitian et al.	Mar 2010	B2
7681579	Schwartz	Mar 2010	B2
7771421	Stewart et al.	Aug 2010	B2
7805182	Weese et al.	Sep 2010	B2
7842031	Abboud	Nov 2010	B2
7850642	Moll et al.	Dec 2010	B2
7850685	Kunis et al.	Dec 2010	B2
7857808	Oral et al.	Dec 2010	B2
7857809	Drysen	Dec 2010	B2
7869865	Govari et al.	Jan 2011	B2
7896873	Hiller et al.	Mar 2011	B2
7917211	Zacouto	Mar 2011	B2
7918819	Karmarkar et al.	Apr 2011	B2
7918850	Govari et al.	Apr 2011	B2
7922714	Stevens-Wright	Apr 2011	B2
7955827	Rubinsky et al.	Jun 2011	B2
8048067	Davalos et al.	Nov 2011	B2
8048072	Verin et al.	Nov 2011	B2
8100895	Panos et al.	Jan 2012	B2
8100900	Prinz et al.	Jan 2012	B2
8108069	Stahler et al.	Jan 2012	B2
8133220	Lee et al.	Mar 2012	B2
8137342	Crossman	Mar 2012	B2
8145289	Calabro' et al.	Mar 2012	B2
8147486	Honour et al.	Apr 2012	B2
8160690	Wilfley et al.	Apr 2012	B2
8175680	Panescu	May 2012	B2
8182477	Orszulak et al.	May 2012	B2
8206384	Falwell et al.	Jun 2012	B2
8206385	Stangenes et al.	Jun 2012	B2
8216221	Ibrahim et al.	Jul 2012	B2
8221411	Francischelli et al.	Jul 2012	B2
8226648	Paul et al.	Jul 2012	B2
8228065	Wirtz et al.	Jul 2012	B2
8235986	Kulesa et al.	Aug 2012	B2
8235988	Davis et al.	Aug 2012	B2
8251986	Chornenky et al.	Aug 2012	B2
8282631	Davalos et al.	Oct 2012	B2
8287532	Carroll et al.	Oct 2012	B2
8414508	Thapliyal et al.	Apr 2013	B2
8430875	Ibrahim et al.	Apr 2013	B2
8433394	Harlev et al.	Apr 2013	B2
8449535	Deno et al.	May 2013	B2
8454594	Demarais et al.	Jun 2013	B2
8463368	Harlev et al.	Jun 2013	B2
8475450	Govari et al.	Jul 2013	B2
8486063	Werneth et al.	Jul 2013	B2
8500733	Watson	Aug 2013	B2
8535304	Sklar et al.	Sep 2013	B2
8538501	Venkatachalam et al.	Sep 2013	B2
8562588	Hobbs et al.	Oct 2013	B2
8568406	Harlev et al.	Oct 2013	B2
8571635	McGee	Oct 2013	B2
8571647	Harlev et al.	Oct 2013	B2
8585695	Shih	Nov 2013	B2
8588885	Hall et al.	Nov 2013	B2
8597288	Christian	Dec 2013	B2
8608735	Govari et al.	Dec 2013	B2
8628522	Ibrahim et al.	Jan 2014	B2
8632534	Pearson et al.	Jan 2014	B2
8647338	Chornenky et al.	Feb 2014	B2
8708952	Cohen et al.	Apr 2014	B2
8734442	Cao et al.	May 2014	B2
8771267	Kunis et al.	Jul 2014	B2
8795310	Fung et al.	Aug 2014	B2
8808273	Caples et al.	Aug 2014	B2
8808281	Emons et al.	Aug 2014	B2
8834461	Werneth et al.	Sep 2014	B2
8834464	Stewart et al.	Sep 2014	B2
8868169	Narayan et al.	Oct 2014	B2
8876817	Avitall et al.	Nov 2014	B2
8880195	Azure	Nov 2014	B2
8886309	Luther et al.	Nov 2014	B2
8903488	Callas et al.	Dec 2014	B2
8920411	Gelbart et al.	Dec 2014	B2
8926589	Govari	Jan 2015	B2
8932287	Gelbart et al.	Jan 2015	B2
8945117	Bencini	Feb 2015	B2
8979841	Kunis et al.	Mar 2015	B2
8986278	Fung et al.	Mar 2015	B2
9002442	Harley et al.	Apr 2015	B2
9005189	Davalos et al.	Apr 2015	B2
9005194	Oral et al.	Apr 2015	B2
9011425	Fischer et al.	Apr 2015	B2
9044245	Condie et al.	Jun 2015	B2
9055959	Vaska et al.	Jun 2015	B2
9072518	Swanson	Jul 2015	B2
9078667	Besser et al.	Jul 2015	B2
9101374	Hoch et al.	Aug 2015	B1
9113911	Sherman	Aug 2015	B2
9119533	Ghaffari	Sep 2015	B2
9119634	Gelbart et al.	Sep 2015	B2
9131897	Harada et al.	Sep 2015	B2
9155590	Mathur	Oct 2015	B2
9162037	Belson et al.	Oct 2015	B2
9179972	Olson	Nov 2015	B2
9186481	Avitall et al.	Nov 2015	B2
9192769	Donofrio et al.	Nov 2015	B2
9204916	Lalonde	Dec 2015	B2
9211405	Mahapatra et al.	Dec 2015	B2
9216055	Spence et al.	Dec 2015	B2
9233248	Luther et al.	Jan 2016	B2
9237926	Nollert et al.	Jan 2016	B2
9262252	Kirkpatrick et al.	Feb 2016	B2
9277957	Long et al.	Mar 2016	B2
9282910	Narayan et al.	Mar 2016	B2
9289258	Cohen	Mar 2016	B2
9289606	Paul et al.	Mar 2016	B2
9295516	Pearson et al.	Mar 2016	B2
9301801	Scheib	Apr 2016	B2
9375268	Long	Jun 2016	B2
9387031	Stewart et al.	Jul 2016	B2
9414881	Callas et al.	Aug 2016	B2
9468495	Kunis et al.	Oct 2016	B2
9474486	Eliason et al.	Oct 2016	B2
9474574	Ibrahim et al.	Oct 2016	B2
9480525	Lopes et al.	Nov 2016	B2
9486272	Bonyak et al.	Nov 2016	B2
9486273	Lopes et al.	Nov 2016	B2
9492227	Lopes et al.	Nov 2016	B2
9492228	Lopes et al.	Nov 2016	B2
9510888	Lalonde	Dec 2016	B2
9517103	Panescu et al.	Dec 2016	B2
9526573	Lopes et al.	Dec 2016	B2
9532831	Reinders et al.	Jan 2017	B2
9539010	Gagner et al.	Jan 2017	B2
9554848	Stewart et al.	Jan 2017	B2
9554851	Sklar et al.	Jan 2017	B2
9700368	Callas et al.	Jul 2017	B2
9724170	Mickelsen	Aug 2017	B2
9757193	Zarins et al.	Sep 2017	B2
9782099	Williams et al.	Oct 2017	B2
9795442	Salahieh et al.	Oct 2017	B2
9801681	Laske et al.	Oct 2017	B2
9808304	Lalonde	Nov 2017	B2
9861802	Mickelsen	Jan 2018	B2
9913685	Clark et al.	Mar 2018	B2
9931487	Quinn et al.	Apr 2018	B2
9987081	Bowers et al.	Jun 2018	B1
9999465	Long et al.	Jun 2018	B2
10010368	Laske et al.	Jul 2018	B2
10016232	Bowers et al.	Jul 2018	B1
10130423	Viswanathan et al.	Nov 2018	B1
10172673	Viswanathan et al.	Jan 2019	B2
10194818	Williams et al.	Feb 2019	B2
10285755	Stewart et al.	May 2019	B2
10322286	Viswanathan et al.	Jun 2019	B2
10433906	Mickelsen	Oct 2019	B2
10433908	Viswanathan et al.	Oct 2019	B2
10512505	Viswanathan	Dec 2019	B2
10512779	Viswanathan et al.	Dec 2019	B2
10517672	Long	Dec 2019	B2
20010000791	Suorsa et al.	May 2001	A1
20010007070	Stewart et al.	Jul 2001	A1
20010044624	Seraj et al.	Nov 2001	A1
20020052602	Wang et al.	May 2002	A1
20020077627	Johnson et al.	Jun 2002	A1
20020087169	Brock et al.	Jul 2002	A1
20020091384	Hooven et al.	Jul 2002	A1
20020095176	Liddicoat et al.	Jul 2002	A1
20020111618	Stewart et al.	Aug 2002	A1
20020156526	Hlavka et al.	Oct 2002	A1
20020161323	Miller et al.	Oct 2002	A1
20020169445	Jain et al.	Nov 2002	A1
20020177765	Bowe et al.	Nov 2002	A1
20020183638	Swanson	Dec 2002	A1
20030014098	Quijano et al.	Jan 2003	A1
20030018374	Paulos	Jan 2003	A1
20030023287	Edwards et al.	Jan 2003	A1
20030028189	Woloszko et al.	Feb 2003	A1
20030050637	Maguire et al.	Mar 2003	A1
20030114849	Ryan	Jun 2003	A1
20030125729	Hooven et al.	Jul 2003	A1
20030130598	Manning et al.	Jul 2003	A1
20030130711	Pearson et al.	Jul 2003	A1
20030204161	Ferek Petric	Oct 2003	A1
20030229379	Ramsey	Dec 2003	A1
20040039382	Kroll et al.	Feb 2004	A1
20040049181	Stewart et al.	Mar 2004	A1
20040049182	Koblish et al.	Mar 2004	A1
20040082859	Schaer	Apr 2004	A1
20040082948	Stewart et al.	Apr 2004	A1
20040087939	Eggers et al.	May 2004	A1
20040111087	Stern et al.	Jun 2004	A1
20040199157	Palanker et al.	Oct 2004	A1
20040231683	Eng et al.	Nov 2004	A1
20040236360	Cohn et al.	Nov 2004	A1
20040254607	Wittenberger et al.	Dec 2004	A1
20040267337	Hayzelden	Dec 2004	A1
20050033282	Hooven	Feb 2005	A1
20050187545	Hooven et al.	Aug 2005	A1
20050222632	Obino	Oct 2005	A1
20050251130	Boveja et al.	Nov 2005	A1
20050261672	Deem et al.	Nov 2005	A1
20060009755	Sra	Jan 2006	A1
20060009759	Chrisitian et al.	Jan 2006	A1
20060015095	Desinger et al.	Jan 2006	A1
20060015165	Bertolero et al.	Jan 2006	A1
20060024359	Walker et al.	Feb 2006	A1
20060058781	Long	Mar 2006	A1
20060111702	Oral et al.	May 2006	A1
20060142801	Demarais	Jun 2006	A1
20060167448	Kozel	Jul 2006	A1
20060217703	Chornenky et al.	Sep 2006	A1
20060241734	Marshall et al.	Oct 2006	A1
20060264752	Rubinsky et al.	Nov 2006	A1
20060270900	Chin et al.	Nov 2006	A1
20060287648	Schwartz	Dec 2006	A1
20060293730	Rubinsky et al.	Dec 2006	A1
20060293731	Rubinsky et al.	Dec 2006	A1
20070005053	Dando	Jan 2007	A1
20070021744	Creighton	Jan 2007	A1
20070060989	Deem et al.	Mar 2007	A1
20070066972	Ormsby et al.	Mar 2007	A1
20070129721	Phan et al.	Jun 2007	A1
20070129760	Demarais et al.	Jun 2007	A1
20070156135	Rubinsky et al.	Jul 2007	A1
20070167740	Grunewald et al.	Jul 2007	A1
20070167940	Stevens-Wright	Jul 2007	A1
20070173878	Heuser	Jul 2007	A1
20070208329	Ward et al.	Sep 2007	A1
20070225589	Viswanathan	Sep 2007	A1
20070249923	Keenan	Oct 2007	A1
20070260223	Scheibe et al.	Nov 2007	A1
20070270792	Hennemann et al.	Nov 2007	A1
20080009855	Hamou	Jan 2008	A1
20080033426	Machell	Feb 2008	A1
20080065061	Viswanathan	Mar 2008	A1
20080086120	Mirza et al.	Apr 2008	A1
20080091195	Silwa et al.	Apr 2008	A1
20080103545	Bolea et al.	May 2008	A1
20080132885	Rubinsky et al.	Jun 2008	A1
20080161789	Thao et al.	Jul 2008	A1
20080172048	Martin et al.	Jul 2008	A1
20080200913	Viswanathan	Aug 2008	A1
20080208118	Goldman	Aug 2008	A1
20080243214	Koblish	Oct 2008	A1
20080281322	Sherman et al.	Nov 2008	A1
20080300574	Belson et al.	Dec 2008	A1
20080300588	Groth et al.	Dec 2008	A1
20090024084	Khosla et al.	Jan 2009	A1
20090048591	Ibrahim et al.	Feb 2009	A1
20090062788	Long et al.	Mar 2009	A1
20090076500	Azure	Mar 2009	A1
20090105654	Kurth et al.	Apr 2009	A1
20090138009	Viswanathan et al.	May 2009	A1
20090149917	Whitehurst et al.	Jun 2009	A1
20090163905	Winkler et al.	Jun 2009	A1
20090228003	Sinelnikov	Sep 2009	A1
20090240248	Deford et al.	Sep 2009	A1
20090275827	Aiken et al.	Nov 2009	A1
20090281477	Mikus et al.	Nov 2009	A1
20090306651	Schneider	Dec 2009	A1
20100004623	Hamilton et al.	Jan 2010	A1
20100023004	Francischelli et al.	Jan 2010	A1
20100137861	Soroff et al.	Jun 2010	A1
20100185140	Kassab et al.	Jul 2010	A1
20100185186	Longoria	Jul 2010	A1
20100191112	Demarais et al.	Jul 2010	A1
20100191232	Boveda	Jul 2010	A1
20100241185	Mahapatra et al.	Sep 2010	A1
20100261994	Davalos et al.	Oct 2010	A1
20100274238	Klimovitch	Oct 2010	A1
20100280513	Juergen et al.	Nov 2010	A1
20100280539	Miyoshi et al.	Nov 2010	A1
20100292687	Kauphusman et al.	Nov 2010	A1
20100312096	Guttman et al.	Dec 2010	A1
20100312300	Ryu et al.	Dec 2010	A1
20110028962	Werneth et al.	Feb 2011	A1
20110028964	Edwards	Feb 2011	A1
20110040199	Hopenfeld	Feb 2011	A1
20110098694	Long	Apr 2011	A1
20110106221	Neal, II et al.	May 2011	A1
20110130708	Perry et al.	Jun 2011	A1
20110144524	Fish et al.	Jun 2011	A1
20110144633	Govari	Jun 2011	A1
20110160785	Mon et al.	Jun 2011	A1
20110190659	Long et al.	Aug 2011	A1
20110190727	Edmunds et al.	Aug 2011	A1
20110213231	Hall et al.	Sep 2011	A1
20110276047	Sklar et al.	Nov 2011	A1
20110276075	Fung et al.	Nov 2011	A1
20110288544	Verin et al.	Nov 2011	A1
20110288547	Morgan et al.	Nov 2011	A1
20110313417	De La Rama et al.	Dec 2011	A1
20120029512	Willard et al.	Feb 2012	A1
20120046570	Villegas et al.	Feb 2012	A1
20120053581	Wittkampf et al.	Mar 2012	A1
20120059255	Paul et al.	Mar 2012	A1
20120071872	Rubinsky et al.	Mar 2012	A1
20120078320	Schotzko et al.	Mar 2012	A1
20120078343	Fish	Mar 2012	A1
20120089089	Swain et al.	Apr 2012	A1
20120095459	Callas et al.	Apr 2012	A1
20120101413	Beetel et al.	Apr 2012	A1
20120158021	Morrill	Jun 2012	A1
20120165667	Altmann et al.	Jun 2012	A1
20120172859	Condie et al.	Jul 2012	A1
20120172867	Ryu et al.	Jul 2012	A1
20120197100	Razavi et al.	Aug 2012	A1
20120209260	Lambert et al.	Aug 2012	A1
20120220998	Long et al.	Aug 2012	A1
20120265198	Crow et al.	Oct 2012	A1
20120283582	Mahapatra et al.	Nov 2012	A1
20120303019	Zhao et al.	Nov 2012	A1
20120310052	Mahapatra et al.	Dec 2012	A1
20120310230	Willis	Dec 2012	A1
20120310237	Swanson	Dec 2012	A1
20120316557	Sartor et al.	Dec 2012	A1
20130030430	Stewart et al.	Jan 2013	A1
20130060247	Sklar et al.	Mar 2013	A1
20130060248	Sklar et al.	Mar 2013	A1
20130079768	De Luca et al.	Mar 2013	A1
20130090651	Smith	Apr 2013	A1
20130096655	Moffitt et al.	Apr 2013	A1
20130103027	Sklar et al.	Apr 2013	A1
20130103064	Arenson et al.	Apr 2013	A1
20130131662	Wittkampf	May 2013	A1
20130158538	Govari	Jun 2013	A1
20130158621	Ding et al.	Jun 2013	A1
20130172715	Just et al.	Jul 2013	A1
20130172864	Ibrahim et al.	Jul 2013	A1
20130172875	Govari et al.	Jul 2013	A1
20130184702	Neal, II et al.	Jul 2013	A1
20130218157	Callas et al.	Aug 2013	A1
20130226174	Ibrahim et al.	Aug 2013	A1
20130237984	Sklar	Sep 2013	A1
20130253415	Sano et al.	Sep 2013	A1
20130296679	Condie et al.	Nov 2013	A1
20130310829	Cohen	Nov 2013	A1
20130317385	Sklar et al.	Nov 2013	A1
20130331831	Werneth et al.	Dec 2013	A1
20130338467	Grasse et al.	Dec 2013	A1
20140005664	Govari et al.	Jan 2014	A1
20140024911	Harlev et al.	Jan 2014	A1
20140039288	Shih	Feb 2014	A1
20140051993	McGee	Feb 2014	A1
20140052118	Laske et al.	Feb 2014	A1
20140052126	Long et al.	Feb 2014	A1
20140052216	Long et al.	Feb 2014	A1
20140058377	Deem et al.	Feb 2014	A1
20140081113	Cohen et al.	Mar 2014	A1
20140100563	Govari et al.	Apr 2014	A1
20140107644	Falwell et al.	Apr 2014	A1
20140142408	De La Rama et al.	May 2014	A1
20140148804	Ward et al.	May 2014	A1
20140163480	Govari et al.	Jun 2014	A1
20140163546	Govari et al.	Jun 2014	A1
20140171942	Werneth et al.	Jun 2014	A1
20140180035	Anderson	Jun 2014	A1
20140187916	Clark et al.	Jul 2014	A1
20140194716	Diep et al.	Jul 2014	A1
20140194867	Fish et al.	Jul 2014	A1
20140200567	Cox et al.	Jul 2014	A1
20140235986	Harlev et al.	Aug 2014	A1
20140235988	Ghosh	Aug 2014	A1
20140235989	Wodlinger et al.	Aug 2014	A1
20140243851	Cohen et al.	Aug 2014	A1
20140276760	Bonyak et al.	Sep 2014	A1
20140276782	Paskar	Sep 2014	A1
20140276791	Ku et al.	Sep 2014	A1
20140288556	Ibrahim et al.	Sep 2014	A1
20140303721	Fung et al.	Oct 2014	A1
20140343549	Spear et al.	Nov 2014	A1
20140364845	Rashidi	Dec 2014	A1
20140371613	Narayan et al.	Dec 2014	A1
20150005767	Werneth et al.	Jan 2015	A1
20150011995	Avitall et al.	Jan 2015	A1
20150066108	Shi et al.	Mar 2015	A1
20150119674	Fischell et al.	Apr 2015	A1
20150126840	Thakur et al.	May 2015	A1
20150133914	Koblish	May 2015	A1
20150138977	Dacosta	May 2015	A1
20150141978	Subramaniam et al.	May 2015	A1
20150141982	Lee	May 2015	A1
20150142041	Kendale et al.	May 2015	A1
20150148796	Bencini	May 2015	A1
20150150472	Harlev et al.	Jun 2015	A1
20150157402	Kunis et al.	Jun 2015	A1
20150157412	Wallace et al.	Jun 2015	A1
20150164584	Davalos et al.	Jun 2015	A1
20150173824	Davalos et al.	Jun 2015	A1
20150173828	Avitall	Jun 2015	A1
20150174404	Rousso et al.	Jun 2015	A1
20150182740	Mickelsen	Jul 2015	A1
20150196217	Harlev et al.	Jul 2015	A1
20150223726	Harlev et al.	Aug 2015	A1
20150230699	Berul et al.	Aug 2015	A1
20150258344	Tandri et al.	Sep 2015	A1
20150265342	Long et al.	Sep 2015	A1
20150265344	Aktas et al.	Sep 2015	A1
20150272656	Chen	Oct 2015	A1
20150272664	Cohen	Oct 2015	A9
20150272667	Govari et al.	Oct 2015	A1
20150282729	Harlev et al.	Oct 2015	A1
20150289923	Davalos et al.	Oct 2015	A1
20150304879	Dacosta	Oct 2015	A1
20150320481	Cosman et al.	Nov 2015	A1
20150321021	Tandri et al.	Nov 2015	A1
20150342532	Basu et al.	Dec 2015	A1
20150343212	Rousso et al.	Dec 2015	A1
20150351836	Prutchi	Dec 2015	A1
20150359583	Swanson	Dec 2015	A1
20160000500	Salahieh et al.	Jan 2016	A1
20160008061	Fung et al.	Jan 2016	A1
20160008065	Gliner et al.	Jan 2016	A1
20160029960	Toth et al.	Feb 2016	A1
20160038772	Thapliyal et al.	Feb 2016	A1
20160051204	Harlev et al.	Feb 2016	A1
20160051324	Stewart et al.	Feb 2016	A1
20160058493	Neal, II et al.	Mar 2016	A1
20160058506	Spence et al.	Mar 2016	A1
20160066993	Avitall et al.	Mar 2016	A1
20160074679	Thapliyal et al.	Mar 2016	A1
20160095531	Narayan et al.	Apr 2016	A1
20160095642	Deno et al.	Apr 2016	A1
20160095653	Lambert et al.	Apr 2016	A1
20160100797	Mahapatra et al.	Apr 2016	A1
20160100884	Fay et al.	Apr 2016	A1
20160106498	Highsmith et al.	Apr 2016	A1
20160106500	Olson	Apr 2016	A1
20160113709	Maor	Apr 2016	A1
20160113712	Cheung et al.	Apr 2016	A1
20160120564	Kirkpatrick et al.	May 2016	A1
20160128770	Afonso et al.	May 2016	A1
20160166167	Narayan et al.	Jun 2016	A1
20160166310	Stewart et al.	Jun 2016	A1
20160166311	Long et al.	Jun 2016	A1
20160174865	Stewart et al.	Jun 2016	A1
20160183877	Williams et al.	Jun 2016	A1
20160184003	Srimathveeravalli et al.	Jun 2016	A1
20160184004	Hull et al.	Jun 2016	A1
20160213282	Leo et al.	Jul 2016	A1
20160220307	Miller et al.	Aug 2016	A1
20160235470	Callas et al.	Aug 2016	A1
20160249972	Klink	Sep 2016	A1
20160256682	Paul et al.	Sep 2016	A1
20160287314	Arena et al.	Oct 2016	A1
20160310211	Long	Oct 2016	A1
20160324564	Gerlach et al.	Nov 2016	A1
20160324573	Mickelsen et al.	Nov 2016	A1
20160331441	Konings	Nov 2016	A1
20160331459	Townley et al.	Nov 2016	A1
20160338770	Bar-Tal et al.	Nov 2016	A1
20160354142	Pearson et al.	Dec 2016	A1
20160361109	Weaver et al.	Dec 2016	A1
20170001016	De Ridder	Jan 2017	A1
20170035499	Stewart et al.	Feb 2017	A1
20170042449	Deno et al.	Feb 2017	A1
20170042615	Salahieh et al.	Feb 2017	A1
20170056648	Syed et al.	Mar 2017	A1
20170065330	Mickelsen et al.	Mar 2017	A1
20170065339	Mickelsen	Mar 2017	A1
20170065340	Long	Mar 2017	A1
20170065343	Mickelsen	Mar 2017	A1
20170071543	Basu et al.	Mar 2017	A1
20170095291	Harrington et al.	Apr 2017	A1
20170105793	Cao et al.	Apr 2017	A1
20170146584	Daw et al.	May 2017	A1
20170151014	Perfler	Jun 2017	A1
20170151029	Mickelsen	Jun 2017	A1
20170172654	Wittkampf et al.	Jun 2017	A1
20170181795	Debruyne	Jun 2017	A1
20170189097	Viswanathan et al.	Jul 2017	A1
20170215953	Long et al.	Aug 2017	A1
20170245928	Xiao et al.	Aug 2017	A1
20170246455	Athos et al.	Aug 2017	A1
20170312024	Harlev et al.	Nov 2017	A1
20170312025	Harlev et al.	Nov 2017	A1
20170312027	Harlev et al.	Nov 2017	A1
20180001056	Leeflang et al.	Jan 2018	A1
20180028252	Lalonde	Feb 2018	A1
20180042674	Mickelsen	Feb 2018	A1
20180042675	Long	Feb 2018	A1
20180043153	Viswanathan et al.	Feb 2018	A1
20180064488	Long et al.	Mar 2018	A1
20180085160	Viswanathan et al.	Mar 2018	A1
20180093088	Mickelsen	Apr 2018	A1
20180133460	Townley et al.	May 2018	A1
20180161093	Basu et al.	Jun 2018	A1
20180168511	Hall et al.	Jun 2018	A1
20180184982	Basu et al.	Jul 2018	A1
20180193090	de la Rama et al.	Jul 2018	A1
20180200497	Mickelsen	Jul 2018	A1
20180235496	Wu et al.	Aug 2018	A1
20180256109	Wu et al.	Sep 2018	A1
20180280080	Govari et al.	Oct 2018	A1
20180303488	Hill	Oct 2018	A1
20180303543	Stewart et al.	Oct 2018	A1
20180311497	Viswanathan et al.	Nov 2018	A1
20180344202	Bar-Tal et al.	Dec 2018	A1
20180344393	Gruba et al.	Dec 2018	A1
20180360531	Holmes et al.	Dec 2018	A1
20180360534	Teplitsky et al.	Dec 2018	A1
20190015007	Rottmann et al.	Jan 2019	A1
20190015638	Gruba et al.	Jan 2019	A1
20190030328	Stewart et al.	Jan 2019	A1
20190046791	Ebbers et al.	Feb 2019	A1
20190069950	Viswanathan et al.	Mar 2019	A1
20190076179	Babkin et al.	Mar 2019	A1
20190125788	Gruba et al.	May 2019	A1
20190143106	Dewitt et al.	May 2019	A1
20190151015	Viswanathan et al.	May 2019	A1
20190175263	Altmann et al.	Jun 2019	A1
20190183378	Mosesov et al.	Jun 2019	A1
20190183567	Govari et al.	Jun 2019	A1
20190192223	Rankin	Jun 2019	A1
20190201089	Waldstreicher et al.	Jul 2019	A1
20190201688	Olson	Jul 2019	A1
20190209235	Stewart et al.	Jul 2019	A1
20190223948	Stewart et al.	Jul 2019	A1
20190231421	Viswanathan et al.	Aug 2019	A1
20190231425	Waldstreicher et al.	Aug 2019	A1
20190254735	Stewart et al.	Aug 2019	A1
20190269912	Viswanathan et al.	Sep 2019	A1
20190298442	Ogata et al.	Oct 2019	A1
20190307500	Byrd et al.	Oct 2019	A1
20190350647	Ramberg et al.	Nov 2019	A1
20190350649	Sutermeister et al.	Nov 2019	A1
20200008869	Byrd	Jan 2020	A1
20200008870	Gruba et al.	Jan 2020	A1
20200009378	Stewart et al.	Jan 2020	A1
20200038104	Mickelsen	Feb 2020	A1
20200046423	Viswanathan et al.	Feb 2020	A1

Foreign Referenced Citations (97)

Number	Date	Country
1042990	Oct 2000	EP
1125549	Aug 2001	EP
0797956	Jun 2003	EP
1127552	Jun 2006	EP
1340469	Mar 2007	EP
1009303	Jun 2009	EP
2213729	Aug 2010	EP
2425871	Mar 2012	EP
1803411	Aug 2012	EP
2532320	Dec 2012	EP
2587275	May 2013	EP
2663227	Nov 2013	EP
1909678	Jan 2014	EP
2217165	Mar 2014	EP
2376193	Mar 2014	EP
2708181	Mar 2014	EP
2777579	Sep 2014	EP
2934307	Oct 2015	EP
2777585	Jun 2016	EP
2382935	Mar 2018	EP
3111871	Mar 2018	EP
3151773	Apr 2018	EP
3056242	Jul 2018	EP
H06-507797	Sep 1994	JP
2000-508196	Jul 2000	JP
2005-516666	Jun 2005	JP
2006-506184	Feb 2006	JP
2008-538997	Nov 2008	JP
2009-500129	Jan 2009	JP
2011-509158	Mar 2011	JP
2012-050538	Mar 2012	JP
WO 9207622	May 1992	WO
WO 9221278	Dec 1992	WO
WO 9221285	Dec 1992	WO
WO 9407413	Apr 1994	WO
WO 9724073	Jul 1997	WO
WO 9725917	Jul 1997	WO
WO 9737719	Oct 1997	WO
WO 1999004851	Feb 1999	WO
WO 1999022659	May 1999	WO
WO 1999056650	Nov 1999	WO
WO 1999059486	Nov 1999	WO
WO 2002056782	Jul 2002	WO
WO 2003053289	Jul 2003	WO
WO 2003065916	Aug 2003	WO
WO 2004045442	Jun 2004	WO
WO 2004086994	Oct 2004	WO
WO 2005046487	May 2005	WO
WO 2006115902	Nov 2006	WO
WO 2007006055	Jan 2007	WO
WO 2007079438	Jul 2007	WO
WO 2009082710	Jul 2009	WO
WO 2009089343	Jul 2009	WO
WO 2009137800	Nov 2009	WO
WO 2010014480	Feb 2010	WO
WO 2011028310	Mar 2011	WO
WO 2011154805	Dec 2011	WO
WO 2012051433	Apr 2012	WO
WO 2012153928	Nov 2012	WO
WO 2013019385	Feb 2013	WO
WO 2014025394	Feb 2014	WO
WO 2014031800	Feb 2014	WO
WO 2014036439	Mar 2014	WO
WO 2014160832	Oct 2014	WO
WO 2015066322	May 2015	WO
WO 2015099786	Jul 2015	WO
WO 2015103530	Jul 2015	WO
WO 2015103574	Jul 2015	WO
WO 2015130824	Sep 2015	WO
WO 2015140741	Sep 2015	WO
WO 2015143327	Sep 2015	WO
WO 2015171921	Nov 2015	WO
WO 2015175944	Nov 2015	WO
WO 2015192018	Dec 2015	WO
WO 2015192027	Dec 2015	WO
WO 2016059027	Apr 2016	WO
WO 2016060983	Apr 2016	WO
WO 2016081650	May 2016	WO
WO 2016090175	Jun 2016	WO
WO 2017093926	Jun 2017	WO
WO 2017119934	Jul 2017	WO
WO 2017120169	Jul 2017	WO
WO 2017192477	Nov 2017	WO
WO 2017192495	Nov 2017	WO
WO 2017201504	Nov 2017	WO
WO 2017218734	Dec 2017	WO
WO 2018005511	Jan 2018	WO
WO 2018106569	Jun 2018	WO
WO 2018200800	Nov 2018	WO
WO 2019023259	Jan 2019	WO
WO 2019023280	Jan 2019	WO
WO 2019035071	Feb 2019	WO
WO 2019133606	Jul 2019	WO
WO 2019133608	Jul 2019	WO
WO 2019136218	Jul 2019	WO
WO 2019181612	Sep 2019	WO
WO 2019234133	Dec 2019	WO

Non-Patent Literature Citations (94)

Entry
Partial Supplementary European Search Report for European Application No. 13827672.0, dated Mar. 23, 2016, 6 pages.
Supplementary European Search Report for European Application No. 13827672.0, dated Jul. 11, 2016, 12 pages.
Office Action for European Application No. 13827672.0, dated Feb. 5, 2018, 6 pages.
Notice of Reasons for Rejection for Japanese Application No. 2015-526522, dated Mar. 6, 2017, 3 pages.
Office Action for U.S. Appl. No. 14/400,455, dated Mar. 30, 2017, 10 pages.
International Search Report and Written Opinion for International Application No. PCT/US2013/031252, dated Jul. 19, 2013, 12 pages.
Office Action for U.S. Appl. No. 15/819,726, dated Jun. 4, 2018, 17 pages.
Office Action for U.S. Appl. No. 15/917,194, dated Jun. 4, 2018, 17 pages.
Office Action for U.S. Appl. No. 15/917,194, dated Oct. 9, 2018, 13 pages.
First Office Action for Chinese Application No. 201580006848.8, dated Jan. 29, 2018, 15 pages.
Office Action for U.S. Appl. No. 15/201,997, dated Dec. 17, 2018, 17 pages.
International Search Report and Written Opinion for International Application No. PCT/US2018/050660, dated Nov. 26, 2018, 13 pages.
Office Action for European Application No. 15701856.5, dated Dec. 11, 2017, 6 pages.
Notice of Reasons for Rejection for Japanese Application No. 2016-544072, dated Oct. 1, 2018, 11 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/010138, dated Mar. 26, 2015, 14 pages.
International Preliminary Report on Patentability for International Application No. PCT/US2015/010138, dated Jul. 12, 2016, 9 pages.
Supplementary European Search Report for European Application No. 15733297.4, dated Aug. 10, 2017, 7 pages.
Office Action for U.S. Appl. No. 15/201,997, dated Apr. 3, 2017, 6 pages.
Office Action for U.S. Appl. No. 15/201,997, dated Aug. 29, 2017, 12 pages.
Office Action for U.S. Appl. No. 15/201,997, dated Jul. 12, 2018, 12 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/010223, dated Apr. 10, 2015, 19 pages.
International Preliminary Report on Patentability for International Application No. PCT/US2015/010223, dated Jul. 12, 2016, 12 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/029734, dated Nov. 24, 2015, 15 pages.
Office Action for U.S. Appl. No. 15/795,062, dated Dec. 19, 2017, 14 pages.
Office Action for U.S. Appl. No. 15/795,062, dated Apr. 9, 2018, 20 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/031086, dated Oct. 21, 2015, 16 pages.
Office Action for U.S. Appl. No. 15/795,075, dated Feb. 6, 2018, 9 pages.
Office Action for U.S. Appl. No. 15/795,075, dated Jun. 15, 2018, 10 pages.
Extended European Search Report for European Application No. 15849844.4, dated May 3, 2018, 8 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/055105, dated Mar. 1, 2016, 15 pages.
Office Action for U.S. Appl. No. 15/796,255, dated Jan. 10, 2018, 12 pages.
Extended European Search Report for European Application No. 15806855.1, dated Jan. 3, 2018, 8 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/035582, dated Oct. 2, 2015, 17 pages.
Extended European Search Report for European Application No. 15806278.6, dated Feb. 9, 2018, 5 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/035592, dated Oct. 2, 2015, 13 pages.
Office Action for U.S. Appl. No. 15/334,646, dated Jul. 25, 2017, 19 pages.
Office Action for U.S. Appl. No. 15/334,646, dated Nov. 16, 2017, 26 pages.
International Search Report and Written Opinion for International Application No. PCT/US2016/057664, dated Feb. 24, 2017, 11 pages.
Office Action for U.S. Appl. No. 15/796,375, dated Jan. 24, 2018, 25 pages.
Office Action for U.S. Appl. No. 15/796,375, dated May 30, 2018, 26 pages.
Office Action for U.S. Appl. No. 15/796,375, dated Nov. 16, 2018, 27 pages.
International Search Report and Written Opinion for International Application No. PCT/US2017/012099, dated May 18, 2017, 17 pages.
Office Action for U.S. Appl. No. 15/711,266, dated Feb. 23, 2018, 14 pages.
International Search Report and Written Opinion for International Application No. PCT/US2018/029938, dated Aug. 29, 2018, 14 pages.
International Search Report and Written Opinion for International Application No. PCT/US2017/037609, dated Nov. 8, 2017, 13 pages.
Office Action for U.S. Appl. No. 15/672,916, dated Feb. 13, 2018, 16 pages.
Office Action for U.S. Appl. No. 15/672,916, dated Jul. 20, 2018, 23 pages.
Office Action for U.S. Appl. No. 15/499,804, dated Jan. 3, 2018, 20 pages.
Office Action for U.S. Appl. No. 15/794,717, dated Feb. 1, 2018, 10 pages.
International Search Report and Written Opinion for International Application No. PCT/US2018/029552, dated Jun. 29, 2018, 13 pages.
Office Action for U.S. Appl. No. 15/970,404, dated Oct. 9, 2018, 21 pages.
du Pre, B.C. et al., “Minimal coronary artery damage by myocardial electroporation ablation,” Europace, 15(1):144-149 (2013).
Hobbs, E. P., “Investor Relations Update: Tissue Ablation via Irreversible Electroporation (IRE),” Powerpoint (2004), 16 pages.
Lavee, J. et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1202, 10(2), 2007 [Epub Mar. 2007].
Madhavan, M. et al., “Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study,” Pace, 00:1-11 (2016).
Neven, K. et al., “Safety and Feasibility of Closed Chest Epicardial Catheter Ablation Using Electroporation,” Circ Arrhythm Electrophysiol., 7:913-919 (2014).
Neven, K. et al., “Myocardial Lesion Size After Epicardial Electroporation Catheter Ablation After Subxiphoid Puncture,” Circ Arrhythm Electrophysiol., 7(4):728-733 (2014).
Neven, K. et al., “Epicardial linear electroporation ablation and lesion size,” Heart Rhythm, 11:1465-1470 (2014).
van Driel, V.J.H.M. et al., “Pulmonary Vein Stenosis After Catheter Ablation Electroporation Versus Radiofrequency,” Circ Arrhythm Electrophysiol., 7(4):734-738 (2014).
van Driel, V.J.H.M. et al., “Low vulnerability of the right phrenic nerve to electroporation ablation,” Heart Rhythm, 12:1838-1844 (2015).
Wittkampf, F.H. et al., “Myocardial Lesion Depth With Circular Electroporation Ablation,” Circ. Arrhythm Electrophysiol., 5(3):581-586 (2012).
Wittkampf, F.H. et al., “Feasibility of Electroporation for the Creation of Pulmonary Vein Ostial Lesions,” J Cardiovasc Electrophysiol, 22(3):302-309 (Mar. 2011).
Office Action for Canadian Application No. 2,881,462, dated Mar. 19, 2019, 5 pages.
Office Action for Japanese Application No. 2018-036714, dated Jan. 16, 2019, 8 pages.
Office Action for U.S. Appl. No. 15/201,983, dated Apr. 3, 2019, 16 pages.
Office Action for U.S. Appl. No. 15/341,523, dated Jan. 29, 2019, 10 pages.
Office Action for U.S. Appl. No. 15/795,075, dated Apr. 10, 2019, 11 pages.
Office Action for U.S. Appl. No. 15/672,916, dated Apr. 9, 2019, 31 pages.
Partial European Search Report for European Application No. 18170210.1, dated Feb. 14, 2019, 13 pages.
Office Action for U.S. Appl. No. 15/970,404, dated Apr. 12, 2019, 20 pages.
Office Action for U.S. Appl. No. 15/917,194, dated Apr. 29, 2019, 10 pages.
Office Action for U.S. Appl. No. 15/795,062, dated May 3, 2019, 21 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/014226, dated Apr. 29, 2019, 15 pages.
Extended European Search Report for European Application No. 18189811.5, dated May 14, 2019, 7 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/017322, dated May 10, 2019, 15 pages.
Office Action for U.S. Appl. No. 15/341,512, dated Aug. 1, 2019, 19 pages.
Office Action for U.S. Appl. No. 15/341,523, dated Jul. 30, 2019, 8 pages.
Office Action for U.S. Appl. No. 15/795,075, dated Jul. 31, 2019, 12 pages.
Office Action for U.S. Appl. No. 15/484,969, dated Sep. 4, 2019, 12 pages.
Office Action for U.S. Appl. No. 15/354,475, dated May 23, 2019, 7 pages.
Extended European Search Report for European Application No. 16884132.8, dated Jul. 8, 2019, 7 pages.
Office Action for U.S. Appl. No. 16/416,677, dated Aug. 15, 2019, 8 pages.
Extended European Search Report for European Application No. 17736218.3 dated Aug. 23, 2019, 9 pages.
Office Action for U.S. Appl. No. 16/181,027, dated Sep. 4, 2019, 12 pages.
Office Action for U.S. Appl. No. 16/240,066, dated May 29, 2019, 7 pages.
Extended European Search Report for European Application No. 18170210.1, dated May 17, 2019, 11 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/030922, dated Sep. 6, 2019, 12 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/030882, dated Sep. 10, 2019, 17 pages.
Office Action for U.S. Appl. No. 16/405,515, dated Sep. 6, 2019, 9 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/031135, dated Aug. 5, 2019, 11 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/028943, dated Sep. 17, 2019, 17 pages.
Office Action for U.S. Appl. No. 16/375,561, dated Oct. 17, 2019, 15 pages.
Office Action for U.S. Appl. No. 16/595,250, dated Mar. 16, 2020, 7 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/051998, dated Feb. 26, 2020, 11 pages.

Related Publications (1)

	Number	Date	Country
	20200093539 A1	Mar 2020	US

Provisional Applications (1)

	Number	Date	Country
	62734214	Sep 2018	US

Systems, apparatuses, and methods for delivery of pulsed electric field ablative energy to endocardial tissue

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Abstract